var title_f6_26_6560="Contact dermatitis";
var content_f6_26_6560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contact dermatitis from ear drops",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 219px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient receiving ototopical antibiotic drops with persistent pruritis. Note erythema and crusting focused in auricular conchal bowl inferiorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laura A Goguen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6560=[""].join("\n");
var outline_f6_26_6560=null;
var title_f6_26_6561="Transgastr pigtail stents";
var content_f6_26_6561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transgastric pigtail stents to drain a pancreatic pseudocyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of two 10F transgastric double-pigtail stents.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Raj J Shah, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6561=[""].join("\n");
var outline_f6_26_6561=null;
var title_f6_26_6562="Paraneoplastic pemphigus oral findings";
var content_f6_26_6562=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paraneoplastic pemphigus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erosive mucositis in a&nbsp;patient with paraneoplastic pemphigus associated with Castleman's tumor; mucous membrane and cutaneous lesions cleared with tumor removal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Chris Ha, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6562=[""].join("\n");
var outline_f6_26_6562=null;
var title_f6_26_6563="Apical 4-chamber echo HCM";
var content_f6_26_6563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/52853/4chaphcm_conv.mp4?title=Apical+4-chamber+echo+HCM\" style=\"width:360px;height:272px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical 4-chamber echocardiogram in a patient with hypertrophic cardiomyopathy (HCM)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical four-chamber view from a two-dimensional echocardiogram shows apical and mid ventricular hypertrophy. During systole the left ventricular cavity is nearly obliterated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6563=[""].join("\n");
var outline_f6_26_6563=null;
var title_f6_26_6564="Myelodysplastic syndromes (MDS) in adults";
var content_f6_26_6564=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/26/6564/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/26/6564/contributors\" id=\"au6121\">",
"       Elihu H Estey, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/26/6564/contributors\" id=\"au5720\">",
"       Stanley L Schrier, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/26/6564/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/26/6564/contributors\" id=\"se3198\">",
"       Richard A Larson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/26/6564/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/26/6564/contributors\" id=\"de1889\">",
"       Rebecca F Connor, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?6/26/6564?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The myelodysplastic syndromes (MDS, myelodysplasia) are a group of blood disorders associated with low blood counts. Normally, blood cells are produced by the bone marrow (the spongy area in the middle of bones) in a controlled fashion. In MDS, the bone marrow does not function effectively to produce one or more types of blood cells, including red blood cells, white blood cells, and platelets.",
"    </p>",
"    <p>",
"     Each type of blood cell performs a number of functions, including the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Red blood cells carry oxygen throughout the body",
"      </li>",
"      <li>",
"       White blood cells help to protect the body from infection",
"      </li>",
"      <li>",
"       Platelets helps blood to clot normally",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In people with MDS, the bone marrow is unable to produce enough cells to keep up with the number of cells removed by the spleen, liver, and other organs. This leads to a reduced number of cells in the body, increasing the risk of bleeding, infection, and problems related to anemia. Anemia occurs when there is a reduced number of red blood cells, which can cause fatigue, shortness of breath, or heart failure.",
"    </p>",
"    <p>",
"     MDS may occur on its own (called de novo MDS) or 1 to 15 years after being exposed to certain forms of chemotherapy or radiation (called treatment-related MDS). Most people (approximately 75 percent) are older than 60 years when they are diagnosed with MDS, although it can develop during childhood.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Some people with MDS have no symptoms, and are diagnosed after laboratory testing is done for another reason. Most people with MDS seek care due to symptoms of anemia, including fatigue, weakness, becoming tired quickly during activities, chest pain, dizziness, difficulty thinking clearly, or shortness of breath.",
"    </p>",
"    <p>",
"     Less commonly, a person with MDS is diagnosed as a result of an infection, easy bruising, or bleeding. Symptoms such as fever and weight loss are uncommon early in the disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     MDS is primarily diagnosed based upon laboratory testing, which includes the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A complete blood count indicates the number of red and white blood cells, and platelets",
"      </li>",
"      <li>",
"       A blood smear involves examining a small sample of blood under a microscope to examine the number, size, shape, and type of blood cells",
"      </li>",
"      <li>",
"       Cytogenetic analysis examines the blood or bone marrow cells for signs of genetic abnormalities in the chromosomes. Researchers have discovered that the genetic makeup of the cells can vary, which can affect how a particular patient responds to treatment. Interpretation of these studies is very complicated. In general, outcomes are better for patients with normal chromosomes and worse for patients with complex changes in their chromosomes. However, certain chromosomal changes are associated with even better outcomes that those seen with normal chromosomes. Examples of these good changes include loss of the Y chromosome or deletion of the long arm of chromosomes 5 or 20.",
"      </li>",
"      <li>",
"       Bone marrow aspiration and biopsy is performed to remove a sample of bone marrow from inside of a bone (usually the hip bone) and examine it with a microscope to look for abnormal cells.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      TYPES OF MYELODYSPLASTIC SYNDROME",
"     </span>",
"    </p>",
"    <p>",
"     Patients with MDS have been classified into subgroups, based in large part upon the blood counts, the number of abnormal cells in the bone marrow, and the cytogenetic studies. This classification system is called the World Health Organization classification and criteria for the myelodysplastic syndromes. A person's subgroup may change over time, as the disease progresses.",
"    </p>",
"    <p>",
"     Perhaps the most useful clinical classification systems for MDS are the original and revised International Prognostic Scoring Systems (IPSS and IPSS-R, respectively). These models were devised to consider variables such as the percentage of immature blood cells (blasts) in the bone marrow, the type of blood abnormality present, as well as studies of the genetic makeup of the abnormal cells. Based on these criteria, the original IPSS defines four risk groups: low, intermediate-1, intermediate-2, and high-risk groups (",
"     <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"      table 1",
"     </a>",
"     ). Similar information is used by the IPSS-R to define five risk groups: very low, low, intermediate, high, and very high risk groups (",
"     <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Treatment recommendations are based upon the patient's original or revised IPSS risk group; a person with low risk type MDS may live for many years before needing treatment while a person with high-risk type MDS usually needs more immediate treatment, without which",
"     <span class=\"nowrap\">",
"      his/her",
"     </span>",
"     life expectancy may not exceed one to two years.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Other than blood or bone marrow transplantation, there is currently no cure for MDS, although a number of treatment options are available to control symptoms, prevent complications of MDS, and improve quality of life. Not all patients with MDS require immediate treatment. Immediate treatment is indicated for patients with symptoms related to MDS. Patients without symptoms are usually monitored closely for disease progression.",
"    </p>",
"    <p>",
"     For patients with symptoms, our treatment approach is similar to that proposed by the National Comprehensive Cancer Network (NCCN). We choose a treatment based upon the patient's age, performance status (a measure of how well a patient can perform normal daily tasks), and disease characteristics such as the IPSS risk score.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Treatment options",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment options for patients with MDS typically fall into one of three categories:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Supportive care includes the use of antibiotics for infection and transfusions for low blood counts. Supportive care is an important part of the management of all patients with MDS.",
"      </li>",
"      <li>",
"       High intensity treatment is more likely to be associated with &ldquo;treatment-related mortality&rdquo;, may require hospitalization, and includes combination chemotherapy with or without bone marrow transplantation. The trade-off for the higher risk associated with these therapies is a greater chance of effectiveness.",
"      </li>",
"      <li>",
"       Low intensity treatment includes those treatments less likely to produce treatment-related mortality and those that do not require a person to remain in the hospital, and includes use of hematopoietic growth factors, low intensity chemotherapy, immunosuppressive treatments, or a thalidomide derivative.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Treatment recommendations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Our general approach to the treatment of MDS is as follows:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Patients with higher risk MDS (IPSS score greater than 1.5 or IPSS-R score greater than 4.5) who are young and otherwise healthy are generally treated with high intensity therapies (see",
"       <a class=\"local\" href=\"#H16\">",
"        'High intensity treatments'",
"       </a>",
"       below).",
"      </li>",
"      <li>",
"       Patients with lower risk MDS (IPSS score less than 1.5 or IPSS-R score less than 3) are generally treated with low intensity therapy or supportive care alone (see",
"       <a class=\"local\" href=\"#H8\">",
"        'Low intensity treatments'",
"       </a>",
"       below).",
"      </li>",
"      <li>",
"       Patients with intermediate risk MDS (IPSS-R score between 3 and 4.5) can be treated with either approach.",
"      </li>",
"      <li>",
"       Supportive care is an important adjunct to the management of",
"       <strong>",
"        all",
"       </strong>",
"       patients with MDS.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      LOW INTENSITY TREATMENTS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Supportive treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Supportive care includes treatment for the signs or symptoms of MDS, including a low white blood cell, platelet, or red blood cell count. Due to the advanced age of most patients with MDS and the chronic nature of the disease, supportive care is an important part of treatment for all patients. These treatments are not intended to cure the disease, although they can improve a person's quality of life and may prolong survival.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Blood transfusions",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a person's red blood cell or platelet count becomes dangerously low, it is possible to give donated blood. A person may donate whole blood or single components, such as red blood cells or platelets. All donated blood and blood products are tested for infectious diseases. Thus, the risk of developing an infection as a result of transfused blood products is now very low. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=see_link\">",
"      \"Patient information: Blood donation and transfusion (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Red blood cells &mdash; Transfusions of red blood cells may be needed to treat signs or symptoms of anemia, including feeling tired or short of breath. If frequent or multiple transfusions of red blood cells are needed, iron overload may occur, which might lead to organ damage. Although controversial, some investigators believe that concern about iron overload should not occur until the patient has received approximately 30 units of packed red blood cells. A treatment called iron chelation may be recommended to remove this excessive iron from the body. Iron chelation treatments can be taken by mouth or as an injection under the skin or into a vein. These treatments have relatively few side effects, although it is unclear if their use prolongs life or improves its quality.",
"      </li>",
"      <li>",
"       Platelets &mdash; Transfusions of platelets may be needed to prevent or treat bleeding problems caused by too few platelets.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Hematopoietic growth factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hematopoietic growth factors are proteins that promote the growth and development of blood cells. The use of growth factors may reduce a person's need for blood transfusions. However, many people with MDS do not respond normally to hematopoietic growth factors because of the bone marrow's defective production of blood cells.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Recombinant human granulocyte colony-stimulating factor (G-CSF, Neupogen) or recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulate white blood cell (granulocyte) production, and may raise the patient's white blood cell count. Use of G-CSF alone is not recommended, except perhaps in the setting of severe infection.",
"      </li>",
"      <li>",
"       Recombinant human erythropoietin (EPO, Procrit, Epogen) promotes the growth of red cells, and decreases the need for red cell transfusions in 20 percent of MDS patients.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Usually, EPO is given alone initially. However, both growth factors are given as combination therapy in some settings.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Low intensity chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy medications in MDS aim to change bone marrow cells to develop more normally, allowing for improved production of red cells, white cells, and platelets. Low doses of a single chemotherapy drug may be recommended for people with lower risk MDS or for people with intermediate or high IPSS scores who cannot tolerate high intensity chemotherapy or bone marrow transplantation.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Azacitidine &mdash; Azacitidine (Vidaza) may increase survival and improve quality of life when compared with supportive treatments alone. Azacitidine is often given to patients with higher risk MDS. While a trial randomizing such patients to &ldquo;best supportive care&rdquo; (principally transfusions) or azacitidine found that survival was longer in the azacitidine group, the median improvement was only about six to nine months.",
"      </li>",
"      <li>",
"       Decitabine &mdash; Decitabine (Dacogen) is similar to azacitidine and appears to increase rates of complete remission. Complete remission means that there are no detectable blasts in the blood or bone marrow and that the bone marrow is functioning normally.",
"      </li>",
"      <li>",
"       Lenalidomide &mdash; Lenalidomide, a thalidomide-like drug, is particularly effective for people with anemia and lower risk MDS with abnormalities of chromosome 5 (called the 5q minus syndrome). Such patients may no longer require red blood cell transfusions after treatment with this agent.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H179019300\">",
"     <span class=\"h2\">",
"      Immunosuppressive drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some patients with MDS, the immune system causes the bone marrow to slow production of blood cells. This may be especially true in people with a reduced number of cells in the bone marrow (called marrow hypoplasia).",
"    </p>",
"    <p>",
"     Some of these patients, particularly those who are younger, with early stage disease and a reduced cell content of the bone marrow, respond to immunosuppressive therapies, which counter this immune attack on the bone marrow, with a resulting increased effective blood cell production. Use of an immunosuppressive therapy may allow between 50 to 60 percent of people who have the HLA DR2 tissue type to discontinue red blood cell transfusions.",
"    </p>",
"    <p>",
"     Examples of immunosuppressive therapies include antithymocyte globulin (ATG) and cyclosporine. ATG is usually given into a vein once per day for four days while cyclosporine is usually taken by mouth twice per day for as long as it is effective.",
"    </p>",
"    <p>",
"     Most everyone who is treated with ATG develops serum sickness, which causes hives, swelling, and fever. This reaction can be minimized by giving steroid treatment along with the ATG.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      HIGH INTENSITY TREATMENTS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      High intensity chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients with intermediate or high risk type MDS may be treated with a chemotherapy regimen similar to that used for treatment of acute myeloid leukemia. In this group, chemotherapy is used to destroy abnormal cells or prevent them from growing. However, this treatment is only recommended if the person is relatively young (eg, &lt;60 years), with a good performance status and normal cytogenetics. High intensity chemotherapy may also be recommended for a person who is eligible for bone marrow (stem cell) transplantation but who has no eligible donor. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=see_link\">",
"      \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     High intensity chemotherapy is not generally recommended for people with a poor performance status, particularly if they are older than 65, or patients age &gt;75. In this group, the expected benefit (prolonged survival) may not be worth the anticipated discomfort, hospitalization, or risk of dying from the toxicity of chemotherapy. The exception would be if the patient were placed on a trial of an investigational therapy with benefits that might plausibly justify the risk.",
"    </p>",
"    <p>",
"     In some patients, supportive care can provide benefits that are equal to standard chemotherapy, with a lower risk of complications or toxicity. It should be stressed, however, that neither alternative is satisfactory prompting interest in clinical trials, many of which are ongoing. Some people do better with an approach that treats MDS-related problems, such as infection or anemia, as they occur, rather than trying to cure the disease. Transfusions and antibiotics can be given as needed in place of more aggressive forms of therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Blood and bone marrow transplantation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bone marrow transplantation (also called hematopoietic stem cell transplantation) is the only known treatment for MDS that has the potential to induce long-term remission or cure. However, transplantation involves the use of high intensity chemotherapy, sometimes with whole body radiation, to eliminate all dividing cells in the bone marrow. Unfortunately, the risks of treatment may be greater than the benefits in some situations.",
"    </p>",
"    <p>",
"     In the past, patients over age 50 were not considered for bone marrow transplantation, mostly due to the risk of transplant-related complications. Improvements have allowed the upper age limit for such transplantation to expand to people age 65 or more. However, approximately 75 percent of patients with MDS are older than 60 at diagnosis, so conventional transplantation can only be offered to a minority of individuals. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"      \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     For treatment of MDS, the optimal source of stem cells is a brother or sister with a similar genetic makeup (ie, a matched related donor). In general, parents, children, and relatives are not suitable donors, since they do not share the same parents and therefore do not have the same genetic material. Improvements in the ability to match unrelated donors has improved over the years and allowed for the transplantation of persons without a matched related donor. A donor's blood (peripheral blood stem cells) has largely replaced bone marrow the source of stem cells.",
"    </p>",
"    <p>",
"     Use of reduced intensity chemotherapy treatment before transplantation may allow some patients with MDS, who would not otherwise be eligible, to undergo transplantation with a lower incidence of transplant-related complications. Reduced intensity regimens use less intensive chemotherapy with low dose or no radiation before transplantation with matched stem cells.",
"    </p>",
"    <p>",
"     Transplantation is recommended for people with higher risk MDS who are under the age of 60 and who have a tissue-matched sibling donor, but not for people with lower risk disease. Although there is a significant chance of cure after bone marrow transplantation in low risk patients (approximately 60 percent), transplant-related deaths and the relapse rate at five years are also high (as high as 40 percent).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      PROGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     For people who are diagnosed with MDS, the average length of survival depends upon the IPSS or IPSS-R risk category, presence of underlying medical problems, and age. It is important to remember that these numbers represent averages, and do not necessarily predict what will happen in your situation. There is considerable variation from patient to patient, especially in the low-risk group.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Many patients will be asked about enrolling in a clinical (research) trial. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask your doctor for more information, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"        www.cancer.gov/clinicaltrials/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287296341\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5519508\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/1/9234?source=see_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5519516\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=see_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26820?source=see_link\">",
"      Patient information: Blood donation and transfusion (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14905?source=see_link\">",
"      Cytogenetics and molecular genetics of myelodysplastic syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17030?source=see_link\">",
"      Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=see_link\">",
"      Hematopoietic cell transplantation in myelodysplastic syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link\">",
"      Overview of the treatment of myelodysplastic syndromes",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Leukemia &amp; Lymphoma Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.leukemia-lymphoma.org/\">",
"      www.leukemia-lymphoma.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/pdq/treatment/myelodysplastic\">",
"      www.cancer.gov/cancertopics/pdq/treatment/myelodysplastic",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Marrow Donor Program",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.marrow.org/\">",
"      www.marrow.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Aplastic Anemia &amp; MDS International Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aamds.org/aplastic/disease_information/myelodysplastic_synd/\">",
"      www.aamds.org/aplastic/disease_information/myelodysplastic_synd/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?6/26/6564/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?6/26/6564?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. WHO classification of Tumors of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6564/abstract/2\">",
"      Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f6_26_6564=[""].join("\n");
var outline_f6_26_6564=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           TYPES OF MYELODYSPLASTIC SYNDROME",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           LOW INTENSITY TREATMENTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           HIGH INTENSITY TREATMENTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           PROGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?26/37/27228\" title=\"table 1\">",
"           IPSS in MDS",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?20/16/20749\" title=\"table 2\">",
"           IPSS-R in MDS",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f6_26_6565="Jorgenson scissors";
var content_f6_26_6565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Jorgenson scissors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right angle Jorgenson scissors are useful in dissection and removal of the cervix.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6565=[""].join("\n");
var outline_f6_26_6565=null;
var title_f6_26_6566="Penicillamine: Pediatric drug information";
var content_f6_26_6566=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penicillamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"    see \"Penicillamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/20/34117?source=see_link\">",
"    see \"Penicillamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cuprimine&reg;;",
"     </li>",
"     <li>",
"      Depen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cuprimine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Copper Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Lead Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Chelating Agent, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"      see \"Penicillamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rheumatoid arthritis:",
"     <b>",
"      Note:",
"     </b>",
"     The optimal duration of therapy has not been determined; in patients experiencing a remission for &ge;6 months, the daily dosage may be decreased in a stepwise fashion in 3-month intervals:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Initial: 3 mg/kg/day (&le;250 mg/day) for 3 months, then 6 mg/kg/day (&le;500 mg/day) in 2 divided doses for 3 months to a maximum of 10 mg/kg/day (&le;1-1.5 g/day) in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 125-250 mg/day, may increase dose by 125-250 mg/day; if therapy still ineffective after 2-3 months of treatment and no signs of adverse effects, increases of 250 mg/day at 2-3 month intervals up to a maximum daily dose of 1.5 g may be done; doses &gt;500 mg/day should be given in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wilson's disease:",
"     <b>",
"      Note:",
"     </b>",
"     Dose that results in an initial 24-hour urinary copper excretion &gt;2 mg/day should be continued for ~3 months; maintenance dose defined by amount resulting in &lt;10 mcg serum free copper/dL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: AASLD guidelines: 20 mg/kg/day in 2-3 divided doses, round off to the nearest 250 mg dose; reduce dose by 25% when clinically stable; administer with a pyridoxine supplement (25-50 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 750-1500 mg/day in divided doses; maximum dose: 2000 mg/day; administer with a pyridoxine supplement (25-50 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In pregnant patients, limit daily dose to 1 g; if a cesarean section is planned, limit daily dose to 250 mg during the last 6 weeks before delivery and postoperatively until the wound has healed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AASLD guidelines recommend to increase tolerability, therapy may be initiated at 250-500 mg/day and then titrated upward by 250 mg every 4-7 days; usual maintenance dose: 750-1000 mg/day in 2 divided doses; maximum: 1000-1500 mg/day in 2-4 divided doses; reduce dose by 25% when clinically stable (Roberts, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cystinuria (doses titrated to maintain urinary cystine excretion at &lt;100-200 mg/day in patients without a history of stones and &lt;100 mg/day in patients who have had stone formation and/or pain):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 30 mg/kg/day in 4 divided doses; maximum dose: 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Initial: 2 g/day divided every 6 hours (range: 1-4 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lead poisoning (treatment duration varies from 4-12 weeks depending upon the pretreatment blood lead level; goal of therapy is to reduce the total body content so that the blood lead level does not rebound to unacceptable levels post-treatment):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 20-30 mg/kg/day in 3-4 divided doses; initiating treatment at 25% of this dose and gradually increasing to the full dose over 2-3 weeks may minimize adverse reactions; maximum dose: 1.5 g/day; a reduced dosage of 15 mg/kg/day in 2 divided doses has been shown to be effective in the treatment of mild to moderate lead poisoning (blood lead concentration 20-40 mcg/dL) with a reduction in adverse effects (Shannon, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1-1.5 g/day in 3-4 divided doses; initiating treatment at 25% of this dose and gradually increasing to the full dose over 2-3 weeks may minimize adverse reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Primary biliary cirrhosis: Adults: 250 mg/day to start, increase by 250 mg every 2 weeks up to a maintenance dose of 1 g/day, as 250 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cuprimine&reg;: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depen&reg;: 250 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer on an empty stomach 1 hour before or 2 hours after meals, milk, or other medications; patients unable to swallow capsules may mix contents of capsule with fruit juice or chilled pureed fruit; patients with cystinuria should drink copious amounts of water",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Wilson's disease, cystinuria, adjunct in the treatment of severe rheumatoid arthritis (FDA approved in adults); has also been used for lead poisoning, primary biliary cirrhosis (as adjunctive therapy following initial treatment with calcium EDTA or BAL); has also been used in lead poisoning",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F207532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Penicillamine may be confused with penicillin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depen [U.S.] may be confused with Depin brand name for nifedipine [India]; Depon brand name for acetaminophen [Greece]; Dipen brand name for diltiazem [Greece]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pemine [Italy] may be confused with Pamine brand name for methscopolamine [U.S., Canada]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F207530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, agitation, fever, Guillain-Barr&eacute; syndrome, hyperpyrexia, psychiatric disturbances, worsening neurologic symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, cheilosis, dermatomyositis, drug eruptions, exfoliative dermatitis, lichen planus, pemphigus, pruritus, rash (early and late), skin friability increased, toxic epidermal necrolysis, urticaria, wrinkling (excessive), yellow nail syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, thyroiditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, epigastric pain, gingivostomatitis, glossitis, nausea, oral ulcerations, pancreatitis, peptic ulcer reactivation, taste alteration, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, leukocytosis, leukopenia, monocytosis, red cell aplasia, sideroblastic anemia, thrombocytopenia, thrombotic thrombocytopenia purpura, thrombocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, hepatic failure, intrahepatic cholestasis, toxic hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis, white papules at venipuncture and surgical sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, dystonia, myasthenia gravis, muscle weakness, neuropathies, polyarthralgia (migratory, often with objective synovitis), polymyositis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia, extraocular muscle weakness, optic neuritis, ptosis, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Goodpasture's syndrome, hematuria, nephrotic syndrome, proteinuria, renal failure, renal vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, interstitial pneumonitis, pulmonary fibrosis, obliterative bronchiolitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic alveolitis, anetoderma, elastosis perforans serpiginosa, lupus-like syndrome, lactic dehydrogenase increased, lymphadenopathy, mammary hyperplasia, positive ANA test",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rheumatoid arthritic patients with renal insufficiency; patients with previous penicillamine-related aplastic anemia or agranulocytosis; concomitant administration with other hematopoietic-depressant drugs (eg, gold, immunosuppressants, antimalarials, phenylbutazone), pregnancy (except for the treatment of Wilson's disease or certain cases of cystinuria), breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients on penicillamine for Wilson's disease or cystinuria should receive pyridoxine supplementation 25-50 mg/day; when treating rheumatoid arthritis, daily pyridoxine supplementation is also recommended. A positive ANA for lupus erythematosus may occur possibly progressing to a lupus-like syndrome. Patients who are allergic to penicillin may theoretically have cross-sensitivity to penicillamine. This possibility has been eliminated now that penicillamine is synthetically produced and no longer contains trace amounts of penicillin.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Penicillamine has been associated with fatalities due to agranulocytosis, aplastic anemia, thrombocytopenia, Goodpasture's syndrome, and myasthenia gravis; discontinue therapy if WBC &lt;3500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; temporarily discontinue treatment if the platelet count is &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; patients should be warned to promptly report any symptoms suggesting toxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; due to the potential severity of these effects, patients should be monitored closely. Proteinuria and/or hematuria may develop and are early warning signs of membraneous glomerulopathy which can progress to nephrotic syndrome; these symptoms may disappear with continued therapy; close observation is warranted; follow 24-hour urine protein excretion rates; excretion &gt;1 g protein in urine per 24 hours or proteinuria which is progressively increasing requires decreasing the dosage or discontinuation in patients treated for rheumatoid arthritis; in Wilson's disease and cystinuria, the risks versus benefits of continuing must be considered.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Drug fever, sometimes accompanied with a skin eruption, necessitates temporary discontinuation of penicillamine in Wilson's disease and cystinuria patients and discontinuation in rheumatoid arthritic patients. Treatment may be resumed with a small dose and gradually increased to the desired dose once the symptoms have subsided. Early rashes (first few months) associated with penicillamine usually disappear within days after discontinuation of therapy and seldom return when treatment is restarted at a lower dose; late rashes (&gt;6 months of treatment) require discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Interruption of continuous therapy for Wilson's disease or cystinuria even for a few days has been associated with sensitivity reactions upon reinstitution of therapy; approximately 33% of patients will experience an allergic reaction. When used for cystinuria, renal stones may develop; an annual x-ray for renal stones is recommended",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: PenicillAMINE may decrease the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of PenicillAMINE. Only oral iron salts are a concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of PenicillAMINE. Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction; however, the success of this action is unproven.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1060976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer with milk or food (food decreases absorption by 50%); iron and zinc may decrease drug action; increase dietary intake or supplement with pyridoxine; for Wilson's disease, decrease copper in diet and omit chocolate, nuts, shellfish, mushrooms, liver, raisins, broccoli, and molasses; for lead poisoning, decrease calcium in diet",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F207464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Birth defects, including congenital cutix laxa and associated defects, have been reported in infants following penicillamine exposure during pregnancy. Use for the treatment of rheumatoid arthritis during pregnancy is contraindicated. Use for the treatment of cystinuria only if the possible benefits to the mother outweigh the potential risks to the fetus. Continued treatment of Wilson's disease during pregnancy protects the mother against relapse. Discontinuation has detrimental maternal and fetal effects. Daily dosage should be limited to 750 mg. For planned cesarean section, reduce dose to 250 mg/day for the last 6 weeks of pregnancy, and continue at this dosage until wound healing is complete.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1060963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinalysis, CBC with differential, hemoglobin, and platelet count are recommended twice weekly for the first month then every 2 weeks for 6 months and monthly thereafter; in addition, monitor the patient's skin, lymph nodes, and body temperature; liver function tests are recommended every 6 months; weekly measurements of urinary and blood concentrations of the intoxicating metal are indicated; quantitative 24-hour urine protein at 1- to 2-week intervals initially (first 2-3 months); annual x-ray for renal stones (when used for cystinuria)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Wilson's disease: Periodic ophthalmic exam; 24-hour urinary copper excretion; copper excretion is highest initially after treatment and may exceed 1000 mcg/day; chronic treatment should produce urinary copper excretion of 200-500 mcg/day on treatment; values &lt;200 mcg/day may be due to either noncompliance or overtreatment which may be differentiated by measuring nonceruloplamin bound copper (high in noncompliance and low in overtreatment)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1060967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wilson's disease: Adequate treatment: &ldquo;Free&rdquo; (unbound) serum copper &lt;10 mcg/dL (Free serum copper = Total copper - ceruloplasmin copper); 24-hour urinary copper excretion 200-500 mcg (3-8 micromoles)/day",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chelates with lead, copper, mercury, iron, and other heavy metals to form stable, soluble complexes that are excreted in the urine; depresses circulating IgM rheumatoid factor levels and",
"     <i>",
"      in vitro",
"     </i>",
"     , depresses T-cell but not B-cell activity; combines with cystine to form a more soluble compound which prevents the formation of cystine calculi",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rheumatoid arthritis: 2-3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wilson's disease: 1-3 months",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 40% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 1.7-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily (30% to 60%) in urine as unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/20/34117?source=see_link\">",
"      see \"Penicillamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Possible severe allergic reaction if patient allergic to penicillin; notify physician if unusual bleeding or bruising, or persistent fever, sore throat, or fatigue occur. Report any unexplained cough, shortness of breath, or rash; loss of taste may occur; do not skip or miss doses or discontinue without notifying physician; cystinuric patients should drink copious amounts of fluid particularly before bed and once during the night",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10160042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The racemic mixture interferes with pyridoxine action and is no longer used; however, supplemental pyridoxine is still recommended.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F207459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 50 mg/mL oral suspension may be made with capsules. Mix the contents of sixty 250 mg capsules with 3 g carboxymethylcellulose, 150 g sucrose, 300 mg citric acid, and parabens (methylparaben 120 mg, propylparaben 12 mg). Add quantity of propylene glycol sufficient to make 100 mL, then add quantity of purified water sufficient to make 300 mL. Cherry flavor may be added. Label \"shake well\" and \"refrigerate\". Stable for 30 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     DeCastro FJ, Jaeger RQ, and Rolfe UT, \"An Extemporaneously Prepared Penicillamine Suspension Used to Treat Lead Intoxication,\"",
"     <i>",
"      Hosp Pharm",
"     </i>",
"     , 1977, 2:446-8.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Piomelli S, &ldquo;Childhood Lead Poisoning,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 2002, 49(6):1285-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/26/6566/abstract-text/12580366/pubmed\" id=\"12580366\" target=\"_blank\">",
"        12580366",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts EA, Schilsky ML, and American Association for Study of Liver Diseases (AASLD),\" Diagnosis and Treatment of Wilson Disease: An Update,\"",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2008, 47(6):2089-111.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/26/6566/abstract-text/18506894/pubmed\" id=\"18506894\" target=\"_blank\">",
"        18506894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shannon MW and Townsend MK, &ldquo;Adverse Effects of Reduced-Dose d-Penicillamine in Children With Mild-to-Moderate Lead Poisoning,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(1):15-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/26/6566/abstract-text/10669180/pubmed\" id=\"10669180\" target=\"_blank\">",
"        10669180",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Treatment Guidelines for Lead Exposure in Children. American Academy of Pediatrics Committee on Drugs,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 96(1 Pt 1):155-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/26/6566/abstract-text/7596706 /pubmed\" id=\"7596706 \" target=\"_blank\">",
"        7596706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12685 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6566=[""].join("\n");
var outline_f6_26_6566=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709199\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207480\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207481\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060964\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060958\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207453\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207438\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060969\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060968\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207532\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207530\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060974\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060957\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060956\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299837\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207447\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060976\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207449\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207464\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060963\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060967\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060955\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060972\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060973\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060962\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10160042\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207459\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12685\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12685|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=related_link\">",
"      Penicillamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/20/34117?source=related_link\">",
"      Penicillamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_26_6567="Rivastigmine: Drug information";
var content_f6_26_6567=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rivastigmine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/37/44629?source=see_link\">",
"    see \"Rivastigmine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Exelon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Rivastigmine&reg;;",
"     </li>",
"     <li>",
"      Exelon&reg;;",
"     </li>",
"     <li>",
"      Mylan-Rivastigmine;",
"     </li>",
"     <li>",
"      Novo-Rivastigmine;",
"     </li>",
"     <li>",
"      PMS-Rivastigmine;",
"     </li>",
"     <li>",
"      ratio-Rivastigmine;",
"     </li>",
"     <li>",
"      Sandoz-Rivastigmine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F218950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acetylcholinesterase Inhibitor (Central)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F218923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Exelon&reg; oral solution and capsules are bioequivalent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate Alzheimer's dementia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 1.5 mg twice daily; may increase by 3 mg daily (1.5 mg/dose) every 2 weeks based on tolerability (maximum recommended dose: 6 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If GI adverse events occur, discontinue treatment for several doses then restart at the same or next lower dosage level; antiemetics have been used to control GI symptoms. If treatment is interrupted for longer than several days, restart the treatment at the lowest dose and titrate as previously described.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transdermal patch:",
"     </i>",
"     Initial: 4.6 mg/24 hours; if well tolerated, may titrate (no sooner than every 4 weeks) to 9.5 mg/24 hours (continue as long as therapeutically beneficial), and then to 13.3 mg/24 hours (maximum dose); doses &gt;13.3 mg/24 hours have not been shown to be more effective and are associated with significant increases in adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If intolerance is noted (nausea, vomiting), patch should be removed and treatment interrupted for several days and restarted at the same or lower dosage. If interrupted for more than 3 days, reinitiate at 4.6 mg/24 hours and titrate (no sooner than every 4 weeks) to lowest effective maintenance dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Conversion from oral therapy: If oral daily dose &lt;6 mg, switch to 4.6 mg/24 hours patch; if oral daily dose 6-12 mg, switch to 9.5 mg/24 hours patch. Apply patch on the next day following last oral dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate Parkinson's-related dementia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: 1.5 mg twice daily; may increase by 3 mg daily (1.5 mg/dose) every 4 weeks based on tolerability (maximum recommended dose: 6 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transdermal patch:",
"     </i>",
"     See transdermal dosing for Alzheimer's dementia.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F218924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following oral administration, clearance is significantly lower in patients &gt;60 years of age, but dosage adjustments are not recommended. Age was not associated with exposure in patients treated transdermally. Titrate dose to individual's tolerance. Refer to adult dosing.",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling recommends an initial oral dose of 1.5 mg once daily in patients &gt;85 years of age with low body weight (&lt;50 kg) or serious comorbidities, with a slower titration rate than used for adults.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F218925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Oral: No dosage adjustment required; titrate as tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Transdermal: Moderate-to-severe impairment: Initial and maximum dose: 4.6 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Oral: Initial dose: 1.5 mg once daily; titrate dose at a rate slower than recommended for healthy adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Transdermal: No dosage adjustment provided in manufacturer's labeling (has not been studied); titrate dose cautiously",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F218926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Oral: No dosage adjustment required; titrate as tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Transdermal: Mild-to-moderate impairment: Initial and maximum dose: 4.6 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate impairment: Initial dose: 1.5 mg once daily; titrate dose at a rate slower than recommended for healthy adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment provided in manufacturer's labeling; titrate dose cautiously",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 1.5 mg, 3 mg, 4.5 mg, 6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exelon&reg;: 1.5 mg, 3 mg, 4.5 mg, 6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exelon&reg;: 4.6 mg/24 hours (30s) [5 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total rivastigmine 9 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exelon&reg;: 9.5 mg/24 hours (30s) [10 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total rivastigmine 18 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exelon&reg;: 13.3 mg/24 hours (30s) [15 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total rivastigmine 27 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exelon&reg;: 2 mg/mL (120 mL) [contains sodium benzoate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F218899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Should be administered with meals (breakfast or dinner). Capsule should be swallowed whole. Liquid form, which is available for patients who cannot swallow capsules, can be swallowed directly from syringe or mixed with water, soda, or cold fruit juice. Stir well and drink within 4 hours of mixing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply transdermal patch to upper or lower back (alternatively, may apply to upper arm or chest). Avoid reapplication to same spot of skin for 14 days (eg, may rotate sections of back). Do not apply to red, irritated, or broken skin. Avoid areas of recent application of lotion or powder. After removal, fold patch to press adhesive surfaces together, and discard. Avoid eye contact; wash hands after handling patch. Replace patch every 24 hours. Avoid exposing the patch to external sources of heat (eg, sauna, excessive light) for prolonged periods of time. No more than 1 patch should be applied daily and existing patch must be removed prior to applying new patch.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F218898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of mild-to-moderate dementia associated with Alzheimer's disease or Parkinson&rsquo;s disease",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5685183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe dementia associated with Alzheimer's disease; Lewy body dementia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F218948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Many concentration-related effects are reported at a lower frequency by transdermal route.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (1% to 21%), headache (3% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5% to 47%), vomiting (5% to 31%), diarrhea (&lt;1% to 19%), anorexia (3% to 17%), abdominal pain (1% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Syncope (3%), hypertension (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (1% to 9%), insomnia (1% to 9%), confusion (8%), falling (6% to 8%), depression (4% to 6%), agitation (5%), anxiety (2% to 5%), malaise (5%), somnolence (4% to 5%), hallucinations (4%), aggressiveness (2% to 3%), parkinsonism symptoms worsening (2% to 3%), psychomotor hyperactivity (3%), vertigo (&le;2%), paranoia (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Application site reactions (including erythema &lt;1% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (9%), appetite decreased (3% to 9%), weight loss (3% to 8%), constipation (5%), flatulence (4%), dehydration (2%), eructation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (1% to 7%), urinary incontinence (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (2% to 6%), tremor (1%; up to 10% in Parkinson&rsquo;s patients), back pain (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Accidental trauma (10%), diaphoresis (4%), flu-like syndrome (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergy, anemia, angina, apraxia, atrial fibrillation, AV block, bradycardia, bundle branch block, cardiac arrest, cardiac failure, cholecystitis, diplopia, diverticulitis, gastritis, gastroesophageal reflux, glaucoma, hyper-/hypoglycemia, hypercholesterolemia, hypersensitivity reactions, hypotension, hypothyroidism, ileus, intracranial hemorrhage, mastitis, MI, migraine, neuralgia, pancreatitis, peripheral ischemia, peripheral neuropathy, pneumonia, psychiatric disorders (eg, delirium, depersonalization, psychosis, emotional lability, suicidal ideation or tendencies),  renal failure, respiratory depression, retinopathy, seizure, sick-sinus syndrome, Stevens-Johnson syndrome, sudden cardiac death, supraventricular tachycardia, thrombocytopenia, thrombophlebitis, thrombosis, transient ischemic attack, ulcerative stomatitis, vasovagal syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F218902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to rivastigmine, other carbamate derivatives (eg, neostigmine, pyridostigmine, physostigmine), or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling):  Severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F218886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause dizziness or fatigue; caution patients in regards to driving or operating machinery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal effects: May exacerbate or induce extrapyramidal symptoms; worsening of symptoms (eg, tremor) in patients with Parkinson&rsquo;s disease has been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI effects: Significant nausea/vomiting or anorexia/weight loss are associated with use; occurs more frequently in women and during the titration phase. Nausea/vomiting may be severe, particularly at higher doses. Monitor weight during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vagotonic effects: Cholinesterase inhibitors may have vagotonic effects which may cause bradycardia and/or heart block with or without a history of cardiac disease. Use with caution in patients with sick-sinus syndrome, bradycardia, or conduction abnormalities. Alzheimer's treatment guidelines consider bradycardia to be a relative contraindication for use of centrally-active cholinesterase inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patients at risk of ulcer disease (eg, previous history or NSAID use); may increase gastric acid secretion. Monitor for symptoms of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with COPD and/or asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary tract obstruction: Use with caution in patients with bladder outlet obstruction or prostatic hyperplasia; cholinomimetics may cause or worsen outflow obstructions, including possible exacerbation of BPH symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depolarizing neuromuscular-blocking agents: May exaggerate neuromuscular blockade effects of depolarizing neuromuscular-blocking agents (eg, succinylcholine).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Body weight (low/high): &lt;50 kg: Use with caution due to increased risk of adverse reactions; &gt;100 kg: May require maintenance doses &gt;9.5 mg/24 hours due to approximate inverse relationship between plasma concentration and body weight (in the range 35-100 kg).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Postmarket cases of overdose (including a few fatalities) have been reported in association with medication errors/improper use of rivastigmine transdermal patches. No more than 1 patch should be applied daily and existing patch must be removed prior to applying new patch.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Initiation/interruption of therapy: Should be started at lowest dose and titrated; if treatment is interrupted for &ge;3 days, reinstate at the lowest daily dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F218915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Smoking: Nicotine increases the clearance of rivastigmine by 23%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (due to risk of sedation; may increase GI irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food delays absorption by 90 minutes, lowers C",
"     <sub>",
"      max",
"     </sub>",
"     by 30% and increases AUC by 30%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid ginkgo biloba (may increase cholinergic effects).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Use in women of reproductive age is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F218930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13907415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F218905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsules should be taken with meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F218903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Exelon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (60): $341.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (60): $341.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.5 mg (60): $341.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (60): $341.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Rivastigmine Tartrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 mg (60): $254.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (60): $254.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.5 mg (60): $254.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (60): $254.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 24-hour",
"     </b>",
"     (Exelon Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.6 mg/24 hrs (1): $11.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9.5 mg/24 hrs (1): $11.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     13.3 mg/24 hrs (1): $11.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Exelon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (120 mL): $558.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F218895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Cognitive function at periodic intervals, symptoms of GI intolerance, weight",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F218906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Exelon (AR, AT, AU, BE, BG, BO, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, FI, FR, GB, GR, GT, HK, HN, HU, ID, IE, IL, IT, MT, MX, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, RU, SE, SG, SK, SV, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Exelon Parches (AR, CN, CO, EC);",
"     </li>",
"     <li>",
"      Exelon Patch (AU, BR, HK, IL, MY, NZ, PE, PH, SG, TH);",
"     </li>",
"     <li>",
"      Revelin (TW);",
"     </li>",
"     <li>",
"      RISTIDIC (BG);",
"     </li>",
"     <li>",
"      Rivadem (IN);",
"     </li>",
"     <li>",
"      Rivast (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F218885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A deficiency of cortical acetylcholine is thought to account for some of the symptoms of Alzheimer's disease and the dementia of Parkinson's disease; rivastigmine increases acetylcholine in the central nervous system through reversible inhibition of its hydrolysis by cholinesterase",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F218901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Anticholinesterase activity (CSF): ~10 hours (6 mg oral dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Fasting: Rapid and complete within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.8-2.7 L/kg; penetrates blood-brain barrier (CSF levels are ~40% of plasma levels following oral administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively via cholinesterase-mediated hydrolysis in the brain; metabolite undergoes N-demethylation and/or sulfate conjugation hepatically; CYP minimally involved; linear kinetics at 3 mg twice daily, but nonlinear at higher doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 36% to 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: 1.5 hours; Transdermal patch: 3 hours (after removal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: 1 hour; Transdermal patch: 8-16 hours following first dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (97% as metabolites); feces (0.4%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Emre M, Aarsland D, Albanese A, et al, &ldquo;Rivastigmine for Dementia Associated with Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(24):2509-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/26/6567/abstract-text/15590953/pubmed\" id=\"15590953\" target=\"_blank\">",
"        15590953",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hort J, O'Brien JT, Gainotti G, et al, &ldquo;EFNS Guidelines for the Diagnosis and Management of Alzheimer&rsquo;s Disease,&rdquo;",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      ,  2010, 17(10):1236-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/26/6567/abstract-text/20831773/pubmed\" id=\"20831773\" target=\"_blank\">",
"        20831773",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lefevre G, Sedek G, Jhee SS, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2008, 83(1):106-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/26/6567/abstract-text/17522596/pubmed\" id=\"17522596\" target=\"_blank\">",
"        17522596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miyasaki JM, Shannon K, Voon V, et al, &ldquo;Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review). Report of the Quality Standards Subcommittee of the American Academy of Neurology,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2006, 66(7):996-1002.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/26/6567/abstract-text/16606910/pubmed\" id=\"16606910\" target=\"_blank\">",
"        16606910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/26/6567/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Eijk MM, Roes KC, Honing ML, et al, \"Effect of Rivastigmine as an Adjunct to Usual Care With Haloperidol on Duration of Delirium and Mortality in Critically Ill Patients: A Multicentre, Double-Blind, Placebo-Controlled Randomised Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 376(9755):1829-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/26/6567/abstract-text/21056464/pubmed\" id=\"21056464\" target=\"_blank\">",
"        21056464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winblad B, Cummings J, Andreasen N, et al, &ldquo;A Six-Month Double-Blind, Randomized, Placebo-Controlled Study of a Transdermal Patch in Alzheimer's Disease &minus; Rivastigmine Patch Versus Capsule,&rdquo;",
"      <i>",
"       Int J Geriatr Psychiatry",
"      </i>",
"      , 2007, 22(5):456-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/26/6567/abstract-text/17380489/pubmed\" id=\"17380489\" target=\"_blank\">",
"        17380489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9529 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6567=[""].join("\n");
var outline_f6_26_6567=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218918\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218919\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218950\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218923\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218924\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218925\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218926\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218897\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218882\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218899\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218898\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5685183\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218948\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218902\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218886\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300010\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218891\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218915\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218893\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218904\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218930\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13907415\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218905\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218903\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218895\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218906\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218885\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218901\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9529\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9529|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/37/44629?source=related_link\">",
"      Rivastigmine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_26_6568="Poisonous spiders PI";
var content_f6_26_6568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Poisonous spiders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Most spiders are not dangerous to people. But these 4 spiders can cause painful bites that can also cause other serious symptoms.",
"    <br/>",
"    A) Black widow.",
"    <br/>",
"    B) Brown widow.",
"    <br/>",
"    C) False black widow.",
"    <br/>",
"    D) Female recluse.",
"    <br/>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6568=[""].join("\n");
var outline_f6_26_6568=null;
var title_f6_26_6569="Inherited susceptibility to melanoma";
var content_f6_26_6569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inherited susceptibility to melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/26/6569/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/26/6569/contributors\">",
"     Hensin Tsao, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/26/6569/contributors\">",
"     Michele Jacobs Gabree, MS, CGC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/26/6569/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/26/6569/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/26/6569/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/26/6569/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/26/6569/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/26/6569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of all cancers depends upon the interplay between environmental and genetic factors. The details of these interactions are not clearly understood for most malignancies.",
"   </p>",
"   <p>",
"    For melanoma, the most significant environmental risk factor is solar ultraviolet (UV) radiation exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/1\">",
"     1",
"    </a>",
"    ]. However, this risk is greatly influenced by genetic factors. As an example, skin type, a heritable trait, modifies the risk presented by a given amount of solar exposure. Dark-skinned populations have a much lower incidence of melanoma than fairer-skinned populations exposed to equivalent sunlight. In the United States, African-Americans have approximately 10 percent the risk of Caucasians.",
"   </p>",
"   <p>",
"    Significant progress has been made toward understanding the genes that contribute to inherited susceptibility for melanoma in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/2\">",
"     2",
"    </a>",
"    ]. Uncommon but high-risk alleles contribute to the hereditary cancer phenotype that includes multiple cases of the associated cancer or cancers on one side of the family, multiple primary cancers in a given individual, and early age of onset for a given cancer. With further advances in both genomic technologies and the conceptual framework to isolate more prevalent, but lower risk, alleles, the spectrum of genetic lesions that contribute to melanoma risk can be expected to broaden.",
"   </p>",
"   <p>",
"    The genetic risk factors for melanoma are discussed here, along with potential implications for genetic screening. Other risk factors associated with the development of melanoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HIGH-RISK LOCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma patients who harbor high-risk variant genes for melanoma will often report a family history of melanoma or a personal history of multiple primary melanomas (MPMs). Although it is estimated that 8 to 12 percent of patients with melanoma have a family history of the disease, not all of these individuals have hereditary melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors may contribute to this observation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some cases, the apparent familial inheritance pattern may be due to clustering of sporadic cases in families with common heavy sun exposure and a susceptible skin type.",
"     </li>",
"     <li>",
"      In other situations, coinheritance of modifying genes may enhance or inhibit the apparent penetrance of a high-risk mutation and thus dictate the strength of the family history. Thus, hereditary cancer families may in fact select for the highest risk genotypes, whether these result from a variant in a single locus or a combination of coinherited variants from multiple loci.",
"     </li>",
"     <li>",
"      Some familial cases occur in the setting of the familial atypical multiple mole and melanoma (FAMMM) syndrome, also called the dysplastic nevus syndrome (DNS). This syndrome was originally described in two kindreds in which affected subjects had multiple (over 100) dysplastic (atypical) nevi, and their lifetime cumulative incidence of melanoma approached 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. A family history of melanoma in multiple first degree relatives and younger age at diagnosis are important components of this syndrome. The median age at diagnosis in one series of 23 kindreds was 33, well below that in patients with sporadic melanomas; this difference may be due in part to increased surveillance of subjects from affected families [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/7\">",
"       7",
"      </a>",
"      ]. However, since there is wide clinical variability in the nevus phenotype (such as size and number of moles and degree of irregularity in border and color), there is currently no consensus as to a formal definition of the \"atypical",
"      <span class=\"nowrap\">",
"       mole/melanoma\"",
"      </span>",
"      syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H19#H19\">",
"       \"Risk factors for the development of melanoma\", section on 'FAMMM syndrome and atypical mole syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CDKN2A GENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial attempts to study the inheritance of melanoma were complicated by difficulties in distinguishing clustered sporadic cases with similar nongenetic risk factors from an inherited single-locus predisposition. The description of the FAMMM syndrome in 1978 further confounded the search for single genetic abnormalities because of the clinical and histopathologic variability in the presentation and diagnosis of this disorder. Estimates of the prevalence of sporadic dysplastic nevi range from 4.9 to 53 percent (",
"    <a class=\"graphic graphic_picture graphicRef78689 \" href=\"UTD.htm?30/46/31471\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial clues that chromosome 9p21 contained a melanoma susceptibility locus came from cytogenetic investigations and studies of loss of heterozygosity (LOH) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/10\">",
"     10",
"    </a>",
"    ]. Strong evidence for linkage to this region came from an analysis of 11 melanoma pedigrees in Texas and Utah [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/11\">",
"     11",
"    </a>",
"    ]. Subsequent studies using positional cloning methods isolated a candidate locus that was ultimately designated CDKN2A, cyclin-dependent kinase inhibitor 2A [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This gene has also been called MTS1 (multiple tumor suppressor 1), p16INK4A, and CDKN2. The gene encodes two proteins, p16 and p14ARF, that are transcribed in alternate reading frames through the use of alternative first exons [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/14\">",
"     14",
"    </a>",
"    ]. Germline CDKN2A mutations in melanoma families are usually missense or nonsense changes that impair the function of p16, although rare mutations in p14ARF have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The p16 protein is a negative regulator of cell cycle progression at the",
"    <span class=\"nowrap\">",
"     G1/S",
"    </span>",
"    checkpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. It interacts with the cyclin-dependent kinases (CDK4 or CDK6), enzymes that control early events in the cell cycle, to catalyze phosphorylation of the retinoblastoma family of proteins. A complex of cyclin D and CDK (mutations of CDK4 are also associated with melanoma; see below) together phosphorylate the retinoblastoma gene (RB1) protein, thereby releasing the transcription factor E2F-1 from RB1, and allowing E2F-1 to induce S phase genes. Consequently, the cell proceeds from G1 arrest through S phase. The p16 protein binds to and inhibits CDK4, and thus serves as a brake on cell cycle progression. Inactivating mutations of p16 disrupt its inhibitory function on CDK4, thereby permitting inappropriate progression through the cell cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/20\">",
"     20",
"    </a>",
"    ]. Tumorigenesis may result from an impairment in senescence, cell differentiation, or cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence of mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a variable rate of CDKN2A mutations in patients with hereditary melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/2,16,23-28\">",
"     2,16,23-28",
"    </a>",
"    ]. The most extensive analysis of melanoma families found that the major features associated with an increased frequency of CDKN2A mutations were multiple cases of melanoma in a family, early age at diagnosis, and family members with multiple primary melanomas (MPM) or pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/16\">",
"     16",
"    </a>",
"    ]. Using these criteria, 385 families with three or more patients with melanoma from the Melanoma Genetics Consortium (GenoMel) were compared across various geographical locales. Overall, 39 percent of families had CDKN2A mutations, ranging from 20 percent (32 of 162) in Australia to 45 percent (29 of 65) in North America and 57 percent (89 of 157) in Europe. An increasing number of cases, earlier age of onset, and multiple lesions in a given individual all were associated with germline CDKN2A mutations. The presence of pancreatic cancer in a given family also predicted CDKN2A mutations except for Australian families.",
"   </p>",
"   <p>",
"    Mutation rates for CDKN2A vary in different studies, probably because of design and ascertainment bias. The prevalence of CDKN2A mutations in the general population with melanoma appears to be much lower than that suggested by studies of multiple-case families. This was illustrated by a study of 3550 patients with melanoma, in which 65 CDKN2A mutation carriers were identified (1.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/29\">",
"     29",
"    </a>",
"    ]; the rates of CDKN2A mutations among individuals with a single primary melanoma and multiple primary melanomas were 1.2 and 2.9 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus the apparent higher rate of germline alterations in familial studies may reflect other coinherited risk alleles, increased detection bias, or unknown confounders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mutation penetrance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the penetrance of CDKN2A mutations among carriers vary depending upon the methods of population ascertainment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/29,31\">",
"     29,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the multicenter Genes Environment and Melanoma (GEM) study, history was obtained from 429 first-degree relatives of index cases seeking cases of melanoma [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/29\">",
"       29",
"      </a>",
"      ]. Based upon an analysis of these individuals, the incidence of melanoma in CDKN2A in carriers was estimated to be 14, 24, and 28 percent at 50, 70, and 80 years of age, respectively. This compared to an incidence of melanoma of1.5, 4.5, and 6.2 percent in the relatives of non-CDKN2A carriers, and an estimated 0.6, 1.6, and 2.6 percent in the baseline population.",
"     </li>",
"     <li>",
"      In the Melanoma Genetics Consortium (GenoMel) study, which was based upon 80 families with documented CDKN2A mutations and multiple affected family members, the incidence of melanoma was 30 percent by age 50 and 67 percent by age 80 years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/31\">",
"       31",
"      </a>",
"      ]. As alluded to earlier, the higher penetrance observed in this study at least in part reflects the bias induced by only analyzing families with two or more cases. An interaction between genetic predisposition and environmental factors was suggested in this series by geographic variations. In Europe, the United States, and Australia, mutation penetrance at age 80 years was 58, 76, and 91 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The same factors that influence the incidence of melanoma in the general population (eg, total nevus count, presence of dysplastic nevi, sunburn) also affect CDKN2A penetrance. This was illustrated in a study of 53 melanoma-prone families and 295 families ascertained through probands diagnosed with melanoma but unselected for family history [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/32\">",
"     32",
"    </a>",
"    ]. The presence of both sunburn and a melanoma-predisposing gene increased the risk of melanoma 15 times more than in noncarriers. In families with CDKN2A mutations, total nevus count, dysplastic nevi, and sunburn all significantly increased the risk of developing melanoma. In addition, the presence of variants in the melanocortin-1 receptor (MC1R) gene increases the risk of developing melanoma in CDKN2A carriers. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Melanocortin-1 receptor gene'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     CDKN2A in early onset melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;One common feature of hereditary cancer syndromes is the early age at diagnosis of cancer in affected individuals. This is true in other cancers (hereditary nonpolyposis colon cancer, familial adenomatous colon cancer, familial breast cancer); it has also been described in melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A young age at disease onset is associated with a higher likelihood of a germline mutation for patients with breast and colon cancer. However, this may not be true in melanoma. In one cohort of young patients (median age 32 years) with sporadic melanoma, there was no increase in the prevalence of germline CDKN2A mutations in the absence of a positive family history [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CDKN2A in multiple primary melanomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another feature of inherited cancer predisposition is the development of multiple cancers, and this appears to be true in melanoma.",
"   </p>",
"   <p>",
"    The cumulative probabilities of having a second primary cutaneous melanoma at 1, 5, 10, and 20 years after the initial diagnosis were 1.0, 2.1, 3.2, and 5.3 percent, respectively, in a study based upon the Surveillance, Epidemiology and End Results (SEER) database [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/34\">",
"     34",
"    </a>",
"    ]. Data on the incidence of germline CDKN2A mutations in patients with multiple primary melanomas are variable. In the GEM cohort, 2.9 percent of 1189 patients with multiple primary melanomas had germline CDKN2A mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/29\">",
"     29",
"    </a>",
"    ]. In contrast, in several smaller studies, the incidence of mutations ranged between 8 and 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. The role for genetic screening for patients with multiple primary melanoma is unclear. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Familial melanoma and other malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;CDKN2A mutations are associated with a wide variety of other tumor types and may be among the most common mutations in human cancer. In addition, epidemiologic studies support an association between the risk of melanoma and other tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pancreatic cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be an increased risk of pancreatic cancer in melanoma families [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/27,39\">",
"     27,39",
"    </a>",
"    ]. In one review of 10 melanoma-prone families with CDKN2A mutations that impaired the function of p16, the risk of pancreatic cancer was increased 22-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/27\">",
"     27",
"    </a>",
"    ]. In contrast, there were no cases of pancreatic cancer in nine melanoma-prone families with CDKN2A mutations that did not impair p16 function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27866?source=see_link\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent studies have confirmed the relationship between CDKN2A mutations, hereditary melanoma, and pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/40-46\">",
"     40-46",
"    </a>",
"    ]; no association was noted with pancreatic cancer in melanoma-prone families without CDKN2A mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/40\">",
"     40",
"    </a>",
"    ]. There are no reliable clinical features that distinguish families that develop melanoma alone from those that also develop pancreatic cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Brain tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain tumors have been described in some melanoma-prone kindreds [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/47\">",
"     47",
"    </a>",
"    ] with germline alterations of the p14ARF component of CDKN2A [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/48\">",
"     48",
"    </a>",
"    ]. An exon 1beta splice junction mutational hotspot in p14ARF has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/49\">",
"     49",
"    </a>",
"    ]; the contribution of these changes to the full spectrum of hereditary melanoma remains to be clarified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CYCLIN-DEPENDENT KINASE 4 GENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, p16 inhibits both cyclin-dependent kinase 4 (CDK4) and CDK6, thereby regulating cell cycle progression. Several melanoma families have been described who lack mutations in CDKN2A, but have germline mutations in the CDK4 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/23,41,50\">",
"     23,41,50",
"    </a>",
"    ]. In these families, the mutations were on arginine 24 of CDK4, resulting in a CDK4 protein that is insensitive to inhibition by p16. There are no apparent differences in the phenotype (eg, age at diagnosis, number of melanomas) of families carrying either CDKN2A or CDK4 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     XERODERMA PIGMENTOSUM GENES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with xeroderma pigmentosum (XP) have an extremely high rate of skin cancers, including cutaneous and conjunctival melanomas. In one large series, 22 percent of XP patients developed melanoma, a rate that is at least 1000-fold greater than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Xeroderma pigmentosum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinically, XP has been divided into various complementation groups (XPA to XPG) based on phenotypic variation. All patients with XP demonstrate a defect in the repair of ultraviolet (UV) radiation-induced photoproducts, a process known as nucleotide excision repair (NER). The XPC and XPE genes recognize DNA damage while the XPA gene verifies the damage. XPB and XPD, both with helicase activity, are then recruited to unwind the DNA from 3' to 5' and 5' to 3', respectively. XPF and XPG then incise the DNA at the 5' and 3' ends, respectively. The repair patch is synthesized by proliferating-cell nuclear antigen (PCNA) and DNA polymerase.",
"   </p>",
"   <p>",
"    XP is an extremely rare disorder and full-blown disease does not appear to play a significant role in melanoma burden at the population level. These genetic observations, however, do provide additional support for the role of UV radiation in melanoma tumorigenesis.",
"   </p>",
"   <p>",
"    More common polymorphisms in the XP genes may contribute to the risk for developing melanoma. This possibility was illustrated by a study in 602 non-Hispanic white melanoma patients and 603 age- and sex-matched cancer-free controls who were genotyped for five common, single-nucleotide polymorphisms in the XP genes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/52\">",
"     52",
"    </a>",
"    ]. There was a statistically significant increase in the risk of melanoma with XPD 751",
"    <span class=\"nowrap\">",
"     Lys/Gln",
"    </span>",
"    (adjusted odds ratio [OR] 1.55) and XPD 751",
"    <span class=\"nowrap\">",
"     Gln/Gln",
"    </span>",
"    (OR, 1.66) genotypes compared with the XPD 751",
"    <span class=\"nowrap\">",
"     Lys/Lys",
"    </span>",
"    genotype. In addition, there was a significant risk associated with",
"    <span class=\"nowrap\">",
"     XPD312Asp/Asn",
"    </span>",
"    (OR, 1.54) and XPD312",
"    <span class=\"nowrap\">",
"     Asn/Asn",
"    </span>",
"    (OR, 1.75) genotypes compared with the XPD 312",
"    <span class=\"nowrap\">",
"     Asp/Asp",
"    </span>",
"    genotype. No increased risk was observed in the other three XPC and XPG single-nucleotide polymorphisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LOW TO MODERATE RISK LOCI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     BRCA2 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BRCA2 (OMIM ID *600185) gene encodes a protein that is important in DNA repair. Germline BRCA2 mutations are associated with an increased risk of breast and other cancers. The association between melanoma and germline mutations in the BRCA1 and BRCA2 genes mutations remains under investigation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a report from the Breast Cancer Linkage Consortium, BRCA2 carriers have an increased risk of cutaneous melanoma (relative risk 2.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/53\">",
"     53",
"    </a>",
"    ]. BRCA2 mutations also appear to occur in families with aggregations of ocular melanoma (7 of 62 such families in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have not found an association between melanoma and inherited mutations in BRCA1 and BRCA2. A study of individuals with cutaneous melanoma and Ashkenazi Jewish ancestry detected no germline mutations in the 92 individuals analyzed for the three BRCA Ashkenazi Jewish founder mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/55\">",
"     55",
"    </a>",
"    ]. With respect to ocular melanoma, no germline mutations in BRCA1 or BRCA2 were detected in a cohort of 25 individuals with a personal history of ocular melanoma and a",
"    <span class=\"nowrap\">",
"     personal/family",
"    </span>",
"    history of breast or ovarian cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/56\">",
"     56",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Retinoblastoma gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the cyclin",
"    <span class=\"nowrap\">",
"     D/CDK",
"    </span>",
"    complex phosphorylates the RB1 protein (OMIM ID +180200), allowing cell cycle progression from G1 to S; p16 binds to and inhibits the activities of these three enzymes, functioning as a brake on cell cycle progression. In one large cohort study of retinoblastoma survivors, the mortality from second cancers, including melanoma, was significantly increased [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/57\">",
"     57",
"    </a>",
"    ]. Although germline RB1 mutations have not been reported in patients with melanoma, mutation or loss of RB1 expression has been described in a limited number of melanoma cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Melanocortin-1 receptor gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variants of the alpha melanocyte stimulating hormone receptor gene (MC1R) have been associated with the red",
"    <span class=\"nowrap\">",
"     hair/fair",
"    </span>",
"    skin phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/59\">",
"     59",
"    </a>",
"    ], which is more common in subjects with cutaneous melanoma. In addition, analysis of the MC1R gene in patients with melanoma has shown an increased prevalence of MC1R gene variants compared to healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/60-66\">",
"     60-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated by a study in which the MC1R gene was sequenced in 267 patients with melanoma and 382 control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/60\">",
"     60",
"    </a>",
"    ]. The presence of MC1R variants was associated with a two- to fourfold increase in the risk of melanoma compared to individuals carrying the wild-type MC1R gene. The association between MC1R variants and melanoma was stronger in individuals with fewer additional risk factors (eg, those with dark skin or few nevi). In addition, patients with a variant MC1R gene were three to fourfold more likely to have thick melanomas.",
"   </p>",
"   <p>",
"    There also is evidence that variants of MC1R can interact with other genes involved in the pathogenesis of melanoma. MC1R variants increase the penetrance of CDKN2A [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/67\">",
"     67",
"    </a>",
"    ]. In a GenoMEL study of 815 CDKN2A mutation carriers from 186 families, the presence of one of the four most common MC1R variants was associated with a statistically significant increased risk of melanoma; the presence of two or more variants further increased that risk compared to having just one variant (odds ratios compared to those without an MC1R variant 5.8 and 2.3, respectively).",
"   </p>",
"   <p>",
"    The BRAF oncogene is the most common site for somatic mutations in melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/68\">",
"     68",
"    </a>",
"    ]. Such mutations are more common in melanomas arising in skin that has little chronic sun-induced damage and are less frequent in melanomas associated with severe chronic solar damage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/69\">",
"     69",
"    </a>",
"    ]. In patients with melanoma originating in skin with limited sun-induced damage, somatic mutations of BRAF are strongly associated with the presence of inherited MC1R variants and are less common in patients with wild type MC1R [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     1p22 gene locus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A novel melanoma susceptibility locus has been mapped to chromosome 1p22, but the gene if interest has not yet been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Genome-wide association studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple groups have utilized genome-wide association studies to identify candidate loci associated with increased melanoma risk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/73-77\">",
"     73-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study conducted by the GenoMel consortium included cases and controls from Sweden, Australia, Italy,",
"      <span class=\"nowrap\">",
"       UK/Leiden,",
"      </span>",
"      France and Spain. Cases were selected based on family history of melanoma",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a history of multiple primaries prior to age 40 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/73\">",
"       73",
"      </a>",
"      ]. Variants in the MC1R, TYR, and MTAP genes were associated with an increased risk melanoma.",
"     </li>",
"     <li>",
"      Other studies have found evidence for melanoma risk associated with variants in the ASIP, TYRP1, SLC45A2, TYR, and PLA2G6 genes [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/74-76,78\">",
"       74-76,78",
"      </a>",
"      ]. These findings should be interpreted cautiously, since a biologic mechanism has not yet been elucidated for melanoma risk associated with these loci [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The question of whether or not to screen for germline CDKN2A mutations as a cause of a hereditary predisposition to melanoma is a common source of concern for the practicing clinician.",
"   </p>",
"   <p>",
"    This issue is likely to arise in one of four settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Family history &mdash; Multiple cases of melanoma in a family may suggest that a mutation in the family is playing a role in the cancer development. However, even in a family in which three first-degree relatives are affected with melanoma, the likelihood that this is due to a mutation in the CDKN2A gene is only about 20 to 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/79\">",
"       79",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prevalence of mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early onset melanoma &mdash; Although early onset cancer is typical of other hereditary cancer predisposition syndromes, no clear association has been found between the onset of melanoma prior to age 40 and CDKN2A or CDK4 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/33\">",
"       33",
"      </a>",
"      ]. The lack of utility of screening was illustrated by a study in which a deleterious CDKN2A mutation was identified in only one of 51 patients (2 percent) diagnosed with melanoma prior to age 20 years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/80\">",
"       80",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'CDKN2A in early onset melanoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple primary melanomas &mdash; The best estimate of the incidence of the CDKN2A mutation rate in patients with multiple primary melanomas is approximately 3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/29\">",
"       29",
"      </a>",
"      ], although some studies have shown a higher rate [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/35-38\">",
"       35-38",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'CDKN2A in multiple primary melanomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The occurrence of other associated tumors (eg, pancreatic cancer, breast cancer, brain tumors), either in the patient's personal history or family history, should be taken into account when considering possible hereditary predisposition syndromes. Melanoma and pancreatic cancer have both been associated with mutations in the CDKN2A gene [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/27,40-42\">",
"       27,40-42",
"      </a>",
"      ]. Melanoma and breast cancer may be associated with mutations in the BRCA2 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/54\">",
"       54",
"      </a>",
"      ]. In patients with a known CDKN2A germline mutation, it is probably appropriate to refer the carrier to a gastroenterologist for discussion of pancreatic cancer screening. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Familial melanoma and other malignancies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic testing for CDKN2A is commercially available through several CLIA (Clinical Laboratory Improvement Amendments) approved laboratories. However, both the American Society of Clinical Oncology (ASCO) and the Melanoma Genetics Consortium have recommended that genetic testing for CDKN2A mutations should be carried out in a research setting rather than a clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. These recommendations are based upon the limited data on the efficacy of prevention and surveillance methods, in addition to the difficulty of interpreting such test results.",
"   </p>",
"   <p>",
"    Genetic testing for CDKN2A mutations could potentially increase the motivation for risk-reducing behaviors and frequent surveillance as well as lowered biopsy threshold for suspicious lesions, which might improve survival if a melanoma occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/81,84\">",
"     81,84",
"    </a>",
"    ]. On the other hand, genetic testing could potentially cause psychological distress, lead to unnecessary biopsies in carriers, and reduce motivation for preventive behaviors in those without CDKN2A mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic counseling, with or without genetic testing, may promote awareness in individuals at increased risk for melanoma. A study involving two CDKN2A families concluded that educating patients about genetic testing as well as photoprotection increased reported photoprotective behaviors regardless of mutation status [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/86\">",
"     86",
"    </a>",
"    ]. In addition, knowledge of familial melanoma risks in families who decline genetic testing has been suggested to encourage melanoma risk reducing and early detection behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6569/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most appropriate recommendations for individuals with a CDKN2A mutation are close clinical surveillance and education regarding risk-reducing behaviors (eg, sunscreen use, sun avoidance). There are no chemoprevention regimens or other prophylactic interventions that are known to benefit CDKN2A mutation carriers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=see_link&amp;anchor=H339582288#H339582288\">",
"     \"Screening and early detection of melanoma\", section on 'High-risk individuals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Familial clustering may be due to an inherited genetic risk or common environmental exposure with sporadic clustering. In either case, all family members are at risk and should obtain dermatologic screening and follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chief environmental risk factor associated with cutaneous melanoma is exposure to ultraviolet radiation. This risk is modified by high-risk genetic factors, the most frequent of which are mutations in the CDKN2A tumor suppressor gene. Other genetic factors (CDK4, xeroderma pigmentosum, BRCA2 gene mutations) associated with an increased risk of melanoma have also been identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Families with known germline CDKN2A mutations are characterized by having multiple family members with melanoma, an early age of onset, individuals with multiple primary melanomas, and coexistence with other primary tumors, especially pancreatic cancer. Even in the presence of these criteria, germline mutations of CDKN2A are uncommon outside the context of families with known mutations. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'CDKN2A gene'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients thought to be at increased risk of having an inherited susceptibility to melanoma due to a CDKN2A mutation, we suggest genetic counseling with a qualified healthcare provider to receive education regarding the risks and benefits of genetic testing and to discuss disease expression and the need for formalized testing. (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Genetic testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For individuals with a known CDKN2A mutation, we recommend close clinical surveillance and education regarding melanoma risk-reducing behaviors (eg, sunscreen use, sun avoidance) (",
"    <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"     Grade 1C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=see_link&amp;anchor=H339582288#H339582288\">",
"     \"Screening and early detection of melanoma\", section on 'High-risk individuals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For individuals thought to be at increased risk of having an inherited susceptibility to melanoma in which no germline gene mutation is detected or for individuals who have a personal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family history of melanoma or are identified as carrying a low-moderate risk allele for melanoma, we recommend education regarding melanoma risk-reducing behaviors and surveillance recommendations, which should be based upon the personal and family history (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=see_link\">",
"     \"Primary prevention of melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=see_link&amp;anchor=H1159434#H1159434\">",
"     \"Screening and early detection of melanoma\", section on 'Screening in higher risk groups'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Armstrong BK, English DR. Epidemiologic studies. In: Cutaneous Melanoma, Balch CM, Houghton AN, Milton GW, et al (Eds), JB Lippincott, Philadelphia 1992. p.12.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/2\">",
"      Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998; 16:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/3\">",
"      Rivers JK. Melanoma. Lancet 1996; 347:803.",
"     </a>",
"    </li>",
"    <li>",
"     Greene MH, Fraumeni JF, Jr. The hereditary variant of malignant melanoma. In: Human Malignant Melanoma, Clark WH, Jr, Goldman LI, Mastrangelo MJ (Eds), Grune Stratton, New York 1979. p.139.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/5\">",
"      Clark WH Jr, Reimer RR, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 1978; 114:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/6\">",
"      Lynch HT, Frichot BC 3rd, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978; 15:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/7\">",
"      Goldstein AM, Fraser MC, Clark WH Jr, Tucker MA. Age at diagnosis and transmission of invasive melanoma in 23 families with cutaneous malignant melanoma/dysplastic nevi. J Natl Cancer Inst 1994; 86:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/8\">",
"      Crutcher WA, Sagebiel RW. Prevalence of dysplastic naevi in a community practice. Lancet 1984; 1:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/9\">",
"      Piepkorn M, Meyer LJ, Goldgar D, et al. The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype. J Am Acad Dermatol 1989; 20:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/10\">",
"      Fountain JW, Karayiorgou M, Ernstoff MS, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A 1992; 89:10557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/11\">",
"      Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992; 258:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/12\">",
"      Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/13\">",
"      Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/14\">",
"      Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 2000; 42:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/15\">",
"      Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006; 66:9818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/16\">",
"      Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007; 44:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/17\">",
"      Binni F, Antigoni I, De Simone P, et al. Novel and recurrent p14 mutations in Italian familial melanoma. Clin Genet 2010; 77:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/18\">",
"      Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/19\">",
"      Ohtani N, Zebedee Z, Huot TJ, et al. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 2001; 409:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/20\">",
"      Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/21\">",
"      Sviderskaya EV, Hill SP, Evans-Whipp TJ, et al. p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst 2002; 94:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/22\">",
"      Sviderskaya EV, Gray-Schopfer VC, Hill SP, et al. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst 2003; 95:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/23\">",
"      Soufir N, Avril MF, Chompret A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998; 7:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/24\">",
"      Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994; 8:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/25\">",
"      van der Velden PA, Sandkuijl LA, Bergman W, et al. A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families. Genome Res 1999; 9:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/26\">",
"      Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/27\">",
"      Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/28\">",
"      Bruno W, Ghiorzo P, Battistuzzi L, et al. Clinical genetic testing for familial melanoma in Italy: a cooperative study. J Am Acad Dermatol 2009; 61:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/29\">",
"      Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005; 97:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/30\">",
"      Berwick M, Orlow I, Hummer AJ, et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev 2006; 15:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/31\">",
"      Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002; 94:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/32\">",
"      Chaudru V, Chompret A, Bressac-de Paillerets B, et al. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 2004; 96:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/33\">",
"      Tsao H, Zhang X, Kwitkiwski K, et al. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 2000; 136:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/34\">",
"      Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003; 97:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/35\">",
"      Blackwood MA, Holmes R, Synnestvedt M, et al. Multiple primary melanoma revisited. Cancer 2002; 94:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/36\">",
"      Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998; 338:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/37\">",
"      Auroy S, Avril MF, Chompret A, et al. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 2001; 32:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/38\">",
"      Puig S, Malvehy J, Badenas C, et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 2005; 23:3043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/39\">",
"      de Snoo FA, Bishop DT, Bergman W, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 2008; 14:7151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/40\">",
"      Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000; 87:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/41\">",
"      Goldstein AM, Struewing JP, Chidambaram A, et al. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000; 92:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/42\">",
"      Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995; 333:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/43\">",
"      Ciotti P, Strigini P, Bianchi-Scarr&agrave; G. Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group. N Engl J Med 1996; 334:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/44\">",
"      Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/45\">",
"      Mantelli M, Barile M, Ciotti P, et al. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet 2002; 107:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/46\">",
"      Rulyak SJ, Brentnall TA, Lynch HT, Austin MA. Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer 2003; 98:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/47\">",
"      Azizi E, Friedman J, Pavlotsky F, et al. Familial cutaneous malignant melanoma and tumors of the nervous system. A hereditary cancer syndrome. Cancer 1995; 76:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/48\">",
"      Randerson-Moor JA, Harland M, Williams S, et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001; 10:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/49\">",
"      Harland M, Taylor CF, Chambers PA, et al. A mutation hotspot at the p14ARF splice site. Oncogene 2005; 24:4604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/50\">",
"      Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996; 12:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/51\">",
"      Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994; 130:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/52\">",
"      Li C, Hu Z, Liu Z, et al. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev 2006; 15:2526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/53\">",
"      Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/54\">",
"      Sinilnikova OM, Egan KM, Quinn JL, et al. Germline brca2 sequence variants in patients with ocular melanoma. Int J Cancer 1999; 82:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/55\">",
"      Kadouri L, Temper M, Grenader T, et al. Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin. Fam Cancer 2009; 8:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/56\">",
"      Buecher B, Gauthier-Villars M, Desjardins L, et al. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma. Fam Cancer 2010; 9:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/57\">",
"      Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/58\">",
"      Bartkova J, Lukas J, Guldberg P, et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56:5475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/59\">",
"      Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/60\">",
"      Landi MT, Kanetsky PA, Tsang S, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2005; 97:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/61\">",
"      Valverde P, Healy E, Sikkink S, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996; 5:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/62\">",
"      Palmer JS, Duffy DL, Box NF, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000; 66:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/63\">",
"      Kennedy C, ter Huurne J, Berkhout M, et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001; 117:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/64\">",
"      Box NF, Duffy DL, Chen W, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001; 69:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/65\">",
"      Fargnoli MC, Spica T, Sera F, et al. Re: MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2006; 98:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/66\">",
"      Scherer D, Nagore E, Bermejo JL, et al. Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations. Int J Cancer 2009; 125:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/67\">",
"      Demenais F, Mohamdi H, Chaudru V, et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst 2010; 102:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/68\">",
"      Haluska FG, Tsao H, Wu H, et al. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006; 12:2301s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/69\">",
"      Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/70\">",
"      Landi MT, Bauer J, Pfeiffer RM, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006; 313:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/71\">",
"      Fargnoli MC, Fargnoli MC, Pike K, et al. MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol 2008; 128:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/72\">",
"      Gillanders E, Juo SH, Holland EA, et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003; 73:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/73\">",
"      Bishop DT, Demenais F, Iles MM, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009; 41:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/74\">",
"      Brown KM, Macgregor S, Montgomery GW, et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 2008; 40:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/75\">",
"      Gudbjartsson DF, Sulem P, Stacey SN, et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008; 40:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/76\">",
"      Falchi M, Bataille V, Hayward NK, et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 2009; 41:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/77\">",
"      Udayakumar D, Tsao H. Melanoma genetics: an update on risk-associated genes. Hematol Oncol Clin North Am 2009; 23:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/78\">",
"      Chatzinasiou F, Lill CM, Kypreou K, et al. Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst 2011; 103:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/79\">",
"      Holland EA, Schmid H, Kefford RF, Mann GJ. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 1999; 25:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/80\">",
"      Berg P, Wennberg AM, Tuominen R, et al. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res 2004; 14:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/81\">",
"      Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999; 17:3245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/82\">",
"      Kefford R, Bishop JN, Tucker M, et al. Genetic testing for melanoma. Lancet Oncol 2002; 3:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/83\">",
"      Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010; 28:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/84\">",
"      Kasparian NA, Meiser B, Butow PN, et al. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med 2009; 11:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/85\">",
"      Kasparian NA, Meiser B, Butow PN, et al. Better the devil you know? High-risk individuals' anticipated psychological responses to genetic testing for melanoma susceptibility. J Genet Couns 2006; 15:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/86\">",
"      Aspinwall LG, Leaf SL, Kohlmann W, et al. Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. J Am Acad Dermatol 2009; 60:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6569/abstract/87\">",
"      Loescher LJ, Crist JD, Siaki LA. Perceived intrafamily melanoma risk communication. Cancer Nurs 2009; 32:203.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7624 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-A1721555EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6569=[""].join("\n");
var outline_f6_26_6569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HIGH-RISK LOCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CDKN2A GENE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence of mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mutation penetrance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CDKN2A in early onset melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CDKN2A in multiple primary melanomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Familial melanoma and other malignancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CYCLIN-DEPENDENT KINASE 4 GENE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      XERODERMA PIGMENTOSUM GENES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LOW TO MODERATE RISK LOCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BRCA2 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Retinoblastoma gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Melanocortin-1 receptor gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      1p22 gene locus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Genome-wide association studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7624\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7624|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/46/31471\" title=\"picture 1\">",
"      Dysplastic nevus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27866?source=related_link\">",
"      Epidemiology and risk factors for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=related_link\">",
"      Primary prevention of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=related_link\">",
"      Screening and early detection of melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_26_6570="Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use";
var content_f6_26_6570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/26/6570/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/26/6570/contributors\">",
"     Owen B Samuels, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/26/6570/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/26/6570/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/26/6570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/26/6570/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/26/6570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H548313\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important factor in successful thrombolytic therapy of acute ischemic stroke is early treatment. Nonetheless, selection of appropriate candidates for thrombolysis demands a neurologic evaluation and a neuroimaging study. In addition, the use of thrombolytics for acute stroke requires a system that coordinates emergency services, stroke neurology, intensive care services, neuroimaging, and neurosurgery to provide optimal treatment.",
"   </p>",
"   <p>",
"    This topic will review the use of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment for patients with acute ischemic stroke. The evidence supporting the use of intravenous thrombolysis and other methods of restoring blood flow to salvage ischemic brain tissue is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other aspects of acute ischemic stroke care are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link\">",
"     \"Neuroimaging of acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H548320\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION AND ELIGIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized, controlled trials have shown that intravenous recombinant tissue plasminogen activator (tPA or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    ) therapy is beneficial for select patients with acute ischemic stroke who start treatment within 4.5 hours of symptom onset in expert centers. This evidence is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H2#H2\">",
"     \"Reperfusion therapy for acute ischemic stroke\", section on 'Intravenous thrombolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For eligible patients (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"     table 1",
"    </a>",
"    ) with acute ischemic stroke, we recommend intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    therapy when treatment is initiated within 3 hours of clearly defined symptom onset, and we suggest intravenous alteplase therapy when treatment is initiated within 3 to 4.5 hours of clearly defined symptom onset. This recommendation is in general agreement with current guidelines from the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"     1",
"    </a>",
"    ] and the American College of Chest Physicians (ACCP) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/2\">",
"     2",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    There is no evidence to support withholding intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment from any patient who meets eligibility criteria. Furthermore, retrospective data suggest that patients with stroke mimics who are treated with alteplase have benign outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Among 512 patients in one study who received intravenous alteplase for suspected acute ischemic within 3 hours of symptom onset, a stroke mimic (mainly seizure, migraine, or conversion disorder) was later diagnosed in 69 (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/3\">",
"     3",
"    </a>",
"    ]. None of the patients with a stroke mimic developed an intracerebral hemorrhage or systemic hemorrhage. Another study of similar size and methodology reported comparable findings [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early CT and MRI changes of infarction are important for risk assessment, as are the presence of other clinical variables associated with an increased risk of bleeding following thrombolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H31#H31\">",
"     \"Reperfusion therapy for acute ischemic stroke\", section on 'Variables associated with intracerebral hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend withholding thrombolytic therapy for patients with extensive multilobar infarction with hypodensity involving more than one-third of the cerebral hemisphere on head CT. Minor ischemic changes (ie, early signs of infarction) on CT are not a contraindication to treatment; these include subtle or small areas of hypodensity, loss of gray-white distinction, obscuration of the lentiform nucleus, or the presence of a hyperdense artery sign.",
"   </p>",
"   <p>",
"    We recommend",
"    <strong>",
"     not",
"    </strong>",
"    using intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    for treatment of acute ischemic stroke beyond 4.5 hours of symptom onset.",
"   </p>",
"   <p>",
"    Several risk assessment methods, including the HAT score, the DRAGON score, the Stroke-Thrombolytic Predictive Instrument, and the SPAN-100 index, have been devised to predict the risk of intracerebral hemorrhage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prognosis for patients with acute stroke who are treated with intravenous thrombolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. However, additional validation studies are needed to confirm the utility of these methods before they should be used in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H548341\">",
"    <span class=\"h2\">",
"     Treatment timeline",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Time is brain\": the sooner intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment is initiated after ischemic stroke, the more likely it is to be beneficial. Eligible patients should be treated as quickly as possible within the appropriate 3 or 4.5 hour time limit. To achieve the earliest treatment, current guidelines recommend that the elapsed time to the start of alteplase infusion should be &le;60 minutes from the time of patient arrival in the emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"     1",
"    </a>",
"    ]. The following in-hospital timeline is suggested as a goal for all patients with acute ischemic stroke who are eligible for treatment with intravenous alteplase:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Evaluation by physician - 10 minutes",
"     </li>",
"     <li>",
"      Stroke or neurologic expertise contacted, ie, stroke team - 15 minutes",
"     </li>",
"     <li>",
"      Head CT or MRI scan - 25 minutes",
"     </li>",
"     <li>",
"      Interpretation of neuroimaging scan - 45 minutes",
"     </li>",
"     <li>",
"      Start of treatment - 60 minutes from arrival",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In-hospital treatment delay can occur with any of these steps. Other items that can lead to inordinate delay include initial telephone triage by the stroke physician, obtaining and waiting for results of blood and laboratory tests, obtaining consent, and delivery of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    from the pharmacy to the bedside.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H209963\">",
"    <span class=\"h2\">",
"     Role of eligibility criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus guidelines for thrombolysis in acute stroke include indications for use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"     table 1",
"    </a>",
"    ) and management of hypertension in patients receiving alteplase therapy (",
"    <a class=\"graphic graphic_table graphicRef50725 \" href=\"UTD.htm?33/29/34268\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1,2,10\">",
"     1,2,10",
"    </a>",
"    ]. In early studies, noncompliance with the original eligibility criteria was associated with an increased risk of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Conversely, strict compliance with these criteria excluded some patients who might have benefited from intravenous alteplase treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/14-24\">",
"     14-24",
"    </a>",
"    ]. As examples, patients with recent myocardial infarction and those with spontaneously clearing stroke symptoms or minor and isolated neurologic signs were strictly excluded under the original criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/25\">",
"     25",
"    </a>",
"    ]. As discussed below, the current guidelines also consider age &gt;80 years or a history of both prior stroke and diabetes mellitus as relative exclusions for treatment in the 3 to 4.5 hour time window [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"     1",
"    </a>",
"    ]. However, mounting evidence suggests that there is no valid reason for withholding thrombolysis for any of these exclusionary criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/14,15,17-19,26,27\">",
"     14,15,17-19,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This evidence has led to revision of the criteria (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"     table 1",
"    </a>",
"    ), such that a number of conditions previously considered strict exclusions (including minor or rapidly improving stroke symptoms, major surgery or serious trauma in the previous 14 days, gastrointestinal or urinary tract bleeding in the previous 21 days, myocardial infarction in the previous three months, and seizure at the onset of stroke with postictal neurologic impairments) are now considered relative exclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"     1",
"    </a>",
"    ]. The 2013",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines note that, under some circumstances and with careful consideration of risk-to-benefit, patients may receive fibrinolytic therapy despite the presence of one or more relative contraindications. In addition, the guidelines acknowledge that physicians with expertise in acute stroke care may modify the eligibility criteria.",
"   </p>",
"   <p>",
"    Note that additional exclusion criteria (age &gt;80 years old, an NIHSS score &gt;25, a combination of previous stroke and diabetes, and oral anticoagulant use regardless of INR) were employed to select patients for the ECASS 3 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/28\">",
"     28",
"    </a>",
"    ], which established the benefit of intravenous thrombolysis in the 3 to 4.5 hour time window (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H4#H4\">",
"     \"Reperfusion therapy for acute ischemic stroke\", section on 'Treatment from 3 to 4.5 hours'",
"    </a>",
"    ). However, it is not clear from the evidence that the exclusion criteria between 3 and 4.5 hours should be different than those for the 0 to 3 hour window [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/29\">",
"     29",
"    </a>",
"    ]. The additional exclusions of ECASS 3 were put in place to satisfy safety concerns from the European regulatory agency. These patient subgroups are under-represented in acute stroke trials in the 0 to 3 hour time window as well, so the safety concern is the same for both time windows.",
"   </p>",
"   <p>",
"    Despite the ECASS 3 trial criteria, we do",
"    <strong>",
"     not",
"    </strong>",
"    consider age, high NIHSS score, previous stroke and diabetes, or use of anticoagulants regardless of INR as absolute contraindications to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment in the 3 to 4.5 hour time window. Like all patients, those who present with acute ischemic stroke in this time window require individualized treatment based upon previous functional status and personal preference. Many patients with one or more of these relative exclusions may desire treatment with intravenous thrombolysis despite its associated risks, rather than living with a potentially devastating residual deficit.",
"   </p>",
"   <p>",
"    Some experts advocate a more rational use of thrombolytic therapy that is based not on an arbitrary time window but on pathophysiologic information from modern imaging studies that define the responsible vascular lesion and the location, extent, and (potentially) the reversibility of brain ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/30\">",
"     30",
"    </a>",
"    ]. Such an approach may be considered in expert stroke centers with unfettered access to modern MRI, CT, and ultrasound based technologies, while other centers may be best served by adherence to the guidelines. Although our recommendations are mainly in agreement with current guidelines and eligibility criteria, we recognize that expert stroke centers may select and treat patients with thrombolytic therapy based upon rational protocols and individual circumstances. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17846043\">",
"    <span class=\"h2\">",
"     Use in menstruating women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombolytic therapy has been found to cause an increase in moderate, but not severe, bleeding in menstruating women who have a myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69241755#H69241755\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Menstruating women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there are few data in menstruating women who have received thrombolytic therapy for stroke. In a case report and review of nine women who were reported to be actively menstruating in the NINDS trial, one woman, who had a one-year history of dysfunctional uterine bleeding, required emergent uterine artery ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/31\">",
"     31",
"    </a>",
"    ]. A second woman required transfusion after tPA administration. None of the other women experienced significant increases in bleeding or required transfusion.",
"   </p>",
"   <p>",
"    These findings suggest that tPA can be administered safely to most women with an ischemic stroke who are menstruating. Bleeding may be increased, in particular, on the first day of menstruation when hemostasis is regulated predominantly by platelet plugs and thrombin, as opposed to local mechanical factors during the remainder of the menstrual period. The hemostatic control mechanisms active in women with dysfunctional uterine bleeding differ than with menstruation, and thrombolytic therapy should be used with caution in patients with dysfunctional uterine bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17846222\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient characteristics that can be identified in the emergency department do not predict whether a patient will respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Some patients will accept any risk, including a high risk of death, for an increased chance of avoiding severe permanent disability. Others are more risk averse and prefer to accept disability, especially if there is a chance of recovery over time.",
"   </p>",
"   <p>",
"    Whether to proceed to thrombolysis in an individual patient should be based upon a discussion of the risks and benefits with the patient and family if possible. However, neurologic deficits caused by acute stroke often preclude obtaining informed consent from the patient.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     Alteplase",
"    </a>",
"    is an approved therapy for acute stroke; consent is not required to administer alteplase as an emergent therapy for eligible patients if surrogate consent is not possible.",
"   </p>",
"   <p>",
"    Consent procedures vary among different centers; we explain the risks and benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    as follows:",
"   </p>",
"   <p>",
"    \"There is a treatment for your stroke called",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    that must be given within 4.5 hours after the stroke started. It is a 'clot-buster' drug. Overall, it is estimated that alteplase treatment is 10 times more likely to help than to harm eligible patients when given within 3 hours of stroke onset [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/34\">",
"     34",
"    </a>",
"    ]. The likelihood of benefit decreases with time, but treatment is still more likely to help than harm up to 4.5 hours after the stroke begins. Thus, the potential benefits of this treatment outweigh the risks. However, this treatment has a major risk, since it can cause severe bleeding in the brain in about 1 of every 15 patients. If bleeding occurs in the brain, it can be fatal. When used to treat large numbers of stroke patients, on average the potential benefits of this treatment outweigh the risks; however, in any individual patient it is a very personal decision\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551003\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF BLOOD PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strict blood pressure control is critical prior to and during the first 24 hours after thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The blood pressure must be at or below 185 mmHg systolic and 110 mmHg diastolic before administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      . Patients with blood pressure above this range should be treated with intravenous agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef50725 \" href=\"UTD.htm?33/29/34268\">",
"       table 2",
"      </a>",
"      ). Alternative agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/22/20839?source=see_link\">",
"       enalaprilat",
"      </a>",
"      . If intravenous treatment does not bring the blood pressure into the acceptable range, the patient should not be treated with alteplase because the risk of intracerebral hemorrhage with thrombolytic therapy may be increased [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once thrombolytic therapy has been administered, the blood pressure must be maintained below",
"      <span class=\"nowrap\">",
"       180/105",
"      </span>",
"      mmHg during and for 24 hours following thrombolytic therapy (",
"      <a class=\"graphic graphic_table graphicRef50725 \" href=\"UTD.htm?33/29/34268\">",
"       table 2",
"      </a>",
"      ). Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      are suggested agents of first choice [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"       1",
"      </a>",
"      ]. Frequent blood pressure monitoring is recommended to ensure that the blood pressure remains in the acceptable range. Current guidelines recommend monitoring every 15 minutes for the first 2 hours after starting thrombolytic treatment, then every 30 minutes for the next 6 hours, then every hour until 24 hours after starting treatment. The frequency of blood pressure monitoring should be increased if the systolic blood pressure is &gt;180 mmHg or if the diastolic blood pressure is &gt;105 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations regarding blood pressure control are based on consensus, since there are no data supporting the use of any specific antihypertensive agent or regimen for patients with acute ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal lower end of the range of desired blood pressure is unclear in those requiring antihypertensive treatment for thrombolysis. Maintaining the systolic blood pressure below 180 mmHg is the only guideline recommendation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"     1",
"    </a>",
"    ]. In this situation, there is still a risk of worsening blood flow within the ischemic penumbra if blood pressure is driven too low. Therefore, it is important to be vigilant for excessive blood pressure lowering when using intravenous antihypertensive treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H548362\">",
"    <span class=\"h1\">",
"     INTRAVENOUS ALTEPLASE ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment, all patients require confirmation of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment is commencing within the required 4.5 hour time window after the onset of symptoms",
"     </li>",
"     <li>",
"      There is a persistent, measurable neurologic deficit",
"     </li>",
"     <li>",
"      Eligibility criteria are met",
"     </li>",
"     <li>",
"      The noncontrast head CT or brain MRI is without hemorrhage",
"     </li>",
"     <li>",
"      Blood pressure parameters are met (see",
"      <a class=\"local\" href=\"#H551003\">",
"       'Management of blood pressure'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Two intravenous lines, preferably large bore, are in place",
"     </li>",
"     <li>",
"      Accurate body weight has been determined [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum glucose must be checked to rule out hypoglycemia as a cause of neurologic deficit. Patients with low platelet counts or elevated prothrombin times should be excluded from intravenous thrombolysis, as should patients with elevated blood pressure levels that cannot be reliably controlled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550917\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dedicated intravenous line is required for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , and all patients should have at least one additional large bore intravenous line.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      dose is calculated at 0.9",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of actual body weight, with a maximum dose of 90 mg.",
"     </li>",
"     <li>",
"      Ten percent of the dose is given as an intravenous bolus over one minute, and the remainder infused over one hour.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is advisable to remove any excess",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    from the bottle prior to administration, in order to avoid overdosage if the intravenous pump is inaccurately calibrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550924\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    for acute ischemic stroke should be admitted to an intensive care unit or dedicated stroke unit for at least 24 hours of close neurologic and cardiac monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"     1",
"    </a>",
"    ]. Important measures during the first 24 hours of alteplase treatment include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vital signs and neurologic status should be checked every 15 minutes for two hours, then every 30 minutes for six hours, then every 60 minutes until 24 hours from the start of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      treatment.",
"     </li>",
"     <li>",
"      Blood pressure must be maintained at or below",
"      <span class=\"nowrap\">",
"       180/105",
"      </span>",
"      mmHg during the first 24 hours (see",
"      <a class=\"local\" href=\"#H551003\">",
"       'Management of blood pressure'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Anticoagulant and antithrombotic agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , or antiplatelet drugs, should",
"      <strong>",
"       not",
"      </strong>",
"      be administered for at least 24 hours after the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      infusion is completed.",
"     </li>",
"     <li>",
"      Placement of intra-arterial catheters, indwelling bladder catheters, and nasogastric tubes should be avoided for at least 24 hours if the patient can be safely managed without them.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A follow-up noncontrast head CT scan should be obtained 24 hours after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    is initiated before starting treatment with antiplatelet or anticoagulant agents [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549875\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most feared complication of thrombolytic therapy is symptomatic intracerebral hemorrhage. Asymptomatic intracerebral hemorrhage, systemic bleeding, and angioedema are additional complications that may arise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33561301\">",
"    <span class=\"h2\">",
"     Intracerebral hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical trials of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , the rates of symptomatic intracerebral hemorrhage were 5 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/25,36\">",
"     25,36",
"    </a>",
"    ]. In addition, most community-based studies of intravenous alteplase have shown similar rates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/11,37-39\">",
"     11,37-39",
"    </a>",
"    ]. These studies suggest that intravenous alteplase can be used safely to treat acute ischemic stroke in routine clinical practice as long as strict inclusion and exclusion criteria are adhered to. This conclusion is supported by the following prospective observational reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the CASES study that collected data on 1135 patients treated with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      at 60 centers in Canada, symptomatic intracerebral hemorrhage occurred in 4.6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In the STARS study that enrolled 389 patients treated with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      at 57 centers in the United States, symptomatic intracerebral hemorrhage occurred in 3.3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In the SITS-MOST study that enrolled 6483 patients treated with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      from 285 centers in Europe, many with little previous experience in acute thrombolytic stroke treatment, symptomatic intracerebral hemorrhage (by the NINDS definition [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/25\">",
"       25",
"      </a>",
"      ]) occurred in 7.3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike CASES or STARS, the SITS-MOST study excluded patients who were treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    in violation of eligibility criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/39\">",
"     39",
"    </a>",
"    ], a group that might be expected to have worse outcomes than eligible patients. However, SITS-MOST did not report the percentage of protocol violators treated at its enrolling centers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/40\">",
"     40",
"    </a>",
"    ], and the impact of excluding such patients on the results is uncertain.",
"   </p>",
"   <p>",
"    In contrast to these reports, a community-based study of 70 patients treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    in the Cleveland metropolitan area found that symptomatic intracerebral hemorrhage occurred in 15.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible explanation for the relatively high rate of symptomatic hemorrhage in the Cleveland area study was that some of the centers had little prior experience administering thrombolytic therapy. In contrast, almost all of the site principal investigators in STARS were neurologists who had previous experience treating stroke patients in clinical trials. In addition, deviations from national treatment guidelines were identified in 50 percent of cases in the Cleveland study, compared with 35 percent in STARS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/11,41\">",
"     11,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After initiation of a stroke quality program in the Cleveland region, the rate of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    use increased, while the rates of symptomatic intracerebral hemorrhage and protocol deviations decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/42\">",
"     42",
"    </a>",
"    ]. These results provide additional evidence that intravenous thrombolysis for acute stroke can be used safely in community practice, and that performance improves with time, physician education, and use of standardized stroke protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549640\">",
"    <span class=\"h2\">",
"     Management of symptomatic intracerebral hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic intracerebral hemorrhage should be suspected in any patient who develops sudden neurologic deterioration, a decline in level of consciousness, new headache, nausea and vomiting, or a sudden rise in blood pressure after thrombolytic therapy is administered, especially within the first 24 hours of treatment. In patients with suspected intracerebral hemorrhage, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    infusion should be discontinued and a stat noncontrast head CT or MRI scan should be arranged (",
"    <a class=\"graphic graphic_table graphicRef68717 \" href=\"UTD.htm?21/60/22475\">",
"     table 3",
"    </a>",
"    ). Blood should be drawn for typing and cross matching, and measurement of prothrombin time, activated partial thromboplastin time, platelet count, and fibrinogen.",
"   </p>",
"   <p>",
"    If symptomatic intracerebral hemorrhage is confirmed by CT or MRI, the administration of agents to reverse the effects of thrombolytic and antiplatelet therapy should be considered, including [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ten units of cryoprecipitate to increase the levels of fibrinogen and factor VIII",
"     </li>",
"     <li>",
"      Six to eight units of platelets",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients receiving unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) for any reason, 1 mg of protamine for every 100 U of UFH given in the preceding 4 hours should be considered.",
"   </p>",
"   <p>",
"    These interventions have not been proven to improve outcome after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    -related intracerebral hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/44\">",
"     44",
"    </a>",
"    ], but they have been suggested by national guidelines as a possible treatment plan [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of neurosurgical evacuation in this setting is controversial. However, data from the GUSTO-I trial of thrombolysis for myocardial infarction suggest that surgical evacuation may be effective for intracerebral hemorrhage related to thrombolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/45\">",
"     45",
"    </a>",
"    ]. In that trial, the 30-day survival was significantly higher with evacuation than without (65 versus 35 percent), and there was a trend towards improved functional outcome due to a higher incidence of nondisabling stroke in those with evacuation compared with those without (20 versus 12 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549655\">",
"    <span class=\"h2\">",
"     Systemic bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild systemic bleeding usually occurs in the form of oozing from intravenous catheter sites, ecchymoses (especially under automated blood pressure cuffs), and gum bleeding; these complications do not require cessation of treatment. More serious bleeding, such as from the gastrointestinal or genitourinary system, may require discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    depending on the severity. Rarely, patients who suffer stroke after a recent myocardial infarction can develop bleeding into the pericardium, resulting in life-threatening tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/46\">",
"     46",
"    </a>",
"    ]. Consequently, patients who become hypotensive after alteplase should be evaluated with urgent echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549662\">",
"    <span class=\"h2\">",
"     Angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orolingual angioedema occurs in 1 to 5 percent of patients treated with tPA for ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/38,47\">",
"     38,47",
"    </a>",
"    ], and it is typically mild, transient, and contralateral to the ischemic hemisphere [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients taking angiotensin converting enzyme inhibitors and those with CT evidence of ischemia in the frontal and insular cortex may be at increased risk.",
"   </p>",
"   <p>",
"    Severe orolingual angioedema is rare but may cause partial airway obstruction and require emergent airway management [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1,47,48\">",
"     1,47,48",
"    </a>",
"    ]. CT of the tongue can distinguish hematoma from angioedema in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/49\">",
"     49",
"    </a>",
"    ]. Treating centers should be aware of the potential need for stopping the drug infusion, administering antihistamines and corticosteroids, and intubating patients who develop stridor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H209311\">",
"    <span class=\"h1\">",
"     REDUCING DELAYS TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major source of delay to treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    occurs prior to hospital arrival in patients with symptoms of acute ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/50\">",
"     50",
"    </a>",
"    ]. Factors that appear to contribute to prehospital delay include living alone, consultation with a clinician, family member, or nonrelative (rather than immediately calling emergency services), black race or Latino ancestry, and appraisal of symptoms as not being serious or urgent.",
"   </p>",
"   <p>",
"    A noncontrast head CT is often the principal cause of delay in administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , but neuroimaging with CT or MRI is mandatory for all patients to exclude brain hemorrhage.",
"   </p>",
"   <p>",
"    Efforts to reduce delays to treatment are driven by the knowledge that \"time is brain\"; the sooner intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment is initiated after ischemic stroke, the more likely it is to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H5#H5\">",
"     \"Reperfusion therapy for acute ischemic stroke\", section on 'Pooled data'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To achieve the earliest treatment, the elapsed time to the start of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    infusion should be &le;60 minutes from the",
"    <strong>",
"     time of patient arrival",
"    </strong>",
"    in the emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1,52\">",
"     1,52",
"    </a>",
"    ]. Expedited stroke protocols may have the effect of reducing treatment delays and improving patient outcomes. One such protocol includes the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A benchmark of treatment within 2 hours from",
"      <strong>",
"       time of stroke onset",
"      </strong>",
"     </li>",
"     <li>",
"      In-person triage of all code strokes without telephone triage; the stroke physician on-call proceeds immediately to the bedside",
"     </li>",
"     <li>",
"      Unmixed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (tPA) at the bedside during the evaluation",
"     </li>",
"     <li>",
"      No delays pending coagulation tests, chest x-ray, or stool guaiac unless specifically indicated",
"     </li>",
"     <li>",
"      No delays pending formal neuroimaging interpretation; the on-call stroke physician reads the CT scan",
"     </li>",
"     <li>",
"      No delays pending written consent; verbal consent is obtained if the patient is able to consent or if family members are nearby",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With use of the expedited stroke protocol over a period of two years by a stroke team in California, 103 patients were treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    within 3 hours of acute stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/53\">",
"     53",
"    </a>",
"    ]. Of these, 49 patients (48 percent) were treated within 2 hours, a rate that compares favorably with the 20 to 28 percent treatment rate within 2 hours reported by others [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/38,54\">",
"     38,54",
"    </a>",
"    ]. The expedited stroke protocol appears to be safe, as the rate of symptomatic intracranial hemorrhage was 3.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/53\">",
"     53",
"    </a>",
"    ], which compares favorably with the 6.4 percent rate observed in the NINDS trial that first established the effectiveness of intravenous tPA treatment for acute stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H3#H3\">",
"     \"Reperfusion therapy for acute ischemic stroke\", section on 'Treatment within 3 hours'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H209318\">",
"    <span class=\"h2\">",
"     Coagulation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood coagulation tests are often a major source of in-hospital delay to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/55\">",
"     55",
"    </a>",
"    ]. While previously considered always necessary to determine patient eligibility for treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , coagulation test results prior to initiating treatment are required only for patients with recent use of anticoagulants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"     1",
"    </a>",
"    ]. Coagulation tests might also be useful to exclude rare patients with a bleeding diathesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary data suggest that normal coagulation parameters can be predicted on arrival to the emergency department by assessing three questions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the patient taking an oral anticoagulant?",
"     </li>",
"     <li>",
"      Is the patient taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin?",
"     </li>",
"     <li>",
"      Is the patient on hemodialysis?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective study from 2006 (prior to the advent of newer oral anticoagulant agents) that included 299 patients, \"no\" answers to all three questions predicted normal range prothrombin time (PT) and activated partial thromboplastin time (aPTT) with a sensitivity of 100 percent, suggesting that this simple screen may permit earlier treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    in selected patients with acute stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/55\">",
"     55",
"    </a>",
"    ]. However, alteplase therapy should not be started in any patient with inadequate historical information until the aPTT and either the PT or the international normalized ratio (INR) are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H209325\">",
"    <span class=\"h2\">",
"     Telemedicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating data suggest that intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    treatment for acute ischemic stroke can be performed safely and effectively via telemedicine (telestroke) in situations where local stroke expertise is not routinely or immediately available [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/57-61\">",
"     57-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one such telemedicine network in Germany (TEMPiS), two university-affiliated stroke medical centers and 12 community hospitals were connected by two-way audio and video conference systems providing direct visualization and communication with the patient, and by high speed transmission of CT and MRI images over the internet [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/57\">",
"       57",
"      </a>",
"      ]. The two stroke centers provided round-the-clock availability for consultation with the community hospitals.",
"      <br/>",
"      <br/>",
"      In the acute phase, 115 patients who were treated with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      for ischemic stroke under telemedicine guidance in community hospitals had a nonsignificantly higher rate of symptomatic intracerebral hemorrhage than 110 patients treated in stroke center hospitals (7.8 versus 2.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/58\">",
"       58",
"      </a>",
"      ], but the rate was similar to that observed in patients treated with intravenous tPA in the NINDS trial (6.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/25\">",
"       25",
"      </a>",
"      ]. In-hospital mortality was low in both community and stroke center hospitals (3.5 and 4.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/58\">",
"       58",
"      </a>",
"      ]. At three and six months, similar mortality rates and functional outcomes were seen in the 170 patients treated under telemedicine guidance in community hospitals and in the 132 patients treated at the stroke center hospitals [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial that analyzed 222 patients with acute stroke symptoms who presented to remote hospitals, the rate of appropriate decision making regarding the use of thrombolytic therapy was significantly higher for patients randomly assigned to telemedicine consultation than those assigned to telephone consultation (98 versus 82 percent, odds ratio 10.9, 95% CI 2.7&ndash;44.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/60\">",
"       60",
"      </a>",
"      ]. However, there was no significant difference in secondary measures of functional outcome at three months between the groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current guidelines from the American Heart Association and American Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    support the use of telemedicine in the acute stroke setting when local stroke expertise is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/1,62,63\">",
"     1,62,63",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    concluded that telemedicine using high-quality videoconferencing systems in this setting is useful for patient evaluation with NIH Stroke Scale examination, review of brain CT scans, and thrombolysis decision making. In addition, limited data suggest that telemedicine is cost-effective for acute stroke care [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An ongoing randomized clinical trial is evaluating the use of telemedicine to make remote intravenous tPA treatment decisions before transfer to a stroke unit compared with usual care (ie, immediate transfer to stroke unit) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/26/6570/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=see_link\">",
"       \"Patient information: Ischemic stroke treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H548390\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For eligible patients (",
"      <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"       table 1",
"      </a>",
"      ) with acute ischemic stroke, we recommend intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      therapy, provided that treatment is initiated within 3 hours of clearly defined symptom onset (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients who cannot be treated in less than 3 hours, we suggest intravenous alteplase therapy, provided that treatment is initiated within 3 to 4.5 hours of clearly defined symptom onset (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H548320\">",
"       'Patient selection and eligibility'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H2#H2\">",
"       \"Reperfusion therapy for acute ischemic stroke\", section on 'Intravenous thrombolysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      treatment in the 0 to 3 hour time window, there are additional relative exclusion criteria for the 3 to 4.5 hour time window (",
"      <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"       table 1",
"      </a>",
"      ). However, it is not clear from the evidence that the exclusion criteria between 3 and 4.5 hours should be different than those for the 0 to 3 hour window. Thus, we do",
"      <strong>",
"       not",
"      </strong>",
"      consider age, high NIHSS score, previous stroke and diabetes, or use of anticoagulants regardless of INR as absolute contraindications to treatment in the 3 to 4.5 hour time window. (See",
"      <a class=\"local\" href=\"#H548320\">",
"       'Patient selection and eligibility'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H4#H4\">",
"       \"Reperfusion therapy for acute ischemic stroke\", section on 'Treatment from 3 to 4.5 hours'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest withholding thrombolytic therapy for patients with extensive multilobar infarction with hypodensity involving &gt;33 percent of the cerebral hemisphere on head CT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, minor ischemic changes (ie, early signs of infarction) on CT are not a contraindication to treatment; these include subtle or small areas of hypodensity, loss of gray-white distinction, obscuration of the lentiform nucleus, or the presence of a hyperdense artery sign. (See",
"      <a class=\"local\" href=\"#H548320\">",
"       'Patient selection and eligibility'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H31#H31\">",
"       \"Reperfusion therapy for acute ischemic stroke\", section on 'Variables associated with intracerebral hemorrhage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       not",
"      </strong>",
"      using intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      for treatment of acute ischemic stroke beyond 4.5 hours from symptom onset (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H548320\">",
"       'Patient selection and eligibility'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H5#H5\">",
"       \"Reperfusion therapy for acute ischemic stroke\", section on 'Pooled data'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      \"Time is brain\": the sooner intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      treatment is initiated after ischemic stroke, the more likely it is to be beneficial. Eligible patients should be treated as quickly as possible within the appropriate 3 or 4.5 hour time limit. (See",
"      <a class=\"local\" href=\"#H548341\">",
"       'Treatment timeline'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H209311\">",
"       'Reducing delays to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whether to proceed to thrombolysis in an individual patient should be based upon a discussion of the risks and benefits with the patient and family. Some patients would accept a high risk of death due to hemorrhage in an attempt to improve their chances of escaping permanent aphasia or dependency. Others prefer to avoid interventions that carry significant risk. This discussion needs to occur in the context of the outcome predictors described above. (See",
"      <a class=\"local\" href=\"#H17846222\">",
"       'Informed consent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strict blood pressure control is critical prior to and during the first 24 hours after thrombolytic therapy. The blood pressure must be at or below",
"      <span class=\"nowrap\">",
"       185/110",
"      </span>",
"      mmHg prior to administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      . Once thrombolytic therapy has been administered, blood pressure must be maintained at or below",
"      <span class=\"nowrap\">",
"       180/105",
"      </span>",
"      mmHg for 24 hours following thrombolytic therapy (",
"      <a class=\"graphic graphic_table graphicRef50725 \" href=\"UTD.htm?33/29/34268\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H551003\">",
"       'Management of blood pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      dose is calculated at 0.9",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of actual body weight, with a maximum dose of 90 mg. Ten percent of the dose is given as an intravenous bolus over one minute, and the remainder infused over 1 hour. (See",
"      <a class=\"local\" href=\"#H548362\">",
"       'Intravenous alteplase administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      be started within the first 24 hours of thrombolytic therapy in patients with acute ischemic stroke. Aspirin should be started for most patients 24 to 48 hours after thrombolytic therapy at an initial dose of 325 mg, and continued thereafter at a dose of 150 to 325",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H550924\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most feared complication of thrombolytic therapy is symptomatic intracerebral hemorrhage. Asymptomatic intracerebral hemorrhage, systemic bleeding, and angioedema are additional complications that may arise. (See",
"      <a class=\"local\" href=\"#H549875\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/1\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2013; 44:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/2\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/3\">",
"      Chernyshev OY, Martin-Schild S, Albright KC, et al. Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology 2010; 74:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/4\">",
"      Tsivgoulis G, Alexandrov AV, Chang J, et al. Safety and outcomes of intravenous thrombolysis in stroke mimics: a 6-year, single-care center study and a pooled analysis of reported series. Stroke 2011; 42:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/5\">",
"      Lou M, Safdar A, Mehdiratta M, et al. The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology 2008; 71:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/6\">",
"      Strbian D, Meretoja A, Ahlhelm FJ, et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology 2012; 78:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/7\">",
"      Kent DM, Selker HP, Ruthazer R, et al. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke 2006; 37:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/8\">",
"      McMeekin P, Flynn D, Ford GA, et al. Validating the stroke-thrombolytic predictive instrument in a population in the United kingdom. Stroke 2012; 43:3378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/9\">",
"      Saposnik G, Guzik AK, Reeves M, et al. Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100. Neurology 2013; 80:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/10\">",
"      American College of Emergency Physicians and the American Academy of Neurology. Clinical Policy: Use of intravenous tPA for the management of acute ischemic stroke in the emergency department. Ann Emerg Med 2013; 61:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/11\">",
"      Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/12\">",
"      Tanne D, Bates VE, Verro P, et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology 1999; 53:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/13\">",
"      Lopez-Yunez AM, Bruno A, Williams LS, et al. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001; 32:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/14\">",
"      De Keyser J, Gdovinov&aacute; Z, Uyttenboogaart M, et al. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke 2007; 38:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/15\">",
"      Meretoja A, Putaala J, Tatlisumak T, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010; 41:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/16\">",
"      Tong D. Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine. Neurology 2011; 76:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/17\">",
"      De Silva DA, Manzano JJ, Chang HM, Wong MC. Reconsidering recent myocardial infarction as a contraindication for IV stroke thrombolysis. Neurology 2011; 76:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/18\">",
"      Barreto AD, Martin-Schild S, Hallevi H, et al. Thrombolytic therapy for patients who wake-up with stroke. Stroke 2009; 40:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/19\">",
"      Mishra NK, Ahmed N, Davalos A, et al. Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology 2011; 77:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/20\">",
"      Demaerschalk BM. Challenging the validity of imposing contraindications to thrombolysis for acute ischemic stroke. Neurology 2011; 77:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/21\">",
"      Smith EE, Fonarow GC, Reeves MJ, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke 2011; 42:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/22\">",
"      Tong DC. Avoiding thrombolysis in patients with mild stroke: is it SMART? Stroke 2012; 43:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/23\">",
"      Leira EC, Ludwig BR, Gurol ME, et al. The types of neurological deficits might not justify withholding treatment in patients with low total National Institutes of Health Stroke Scale scores. Stroke 2012; 43:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/24\">",
"      Strbian D, Ahmed N, Wahlgren N, et al. Intravenous thrombolysis in ischemic stroke patients with isolated homonymous hemianopia: analysis of Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke 2012; 43:2695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/25\">",
"      Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/26\">",
"      Baumann CR, Baumgartner RW, Gandjour J, et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke 2006; 37:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/27\">",
"      K&ouml;hrmann M, Nowe T, Huttner HB, et al. Safety and outcome after thrombolysis in stroke patients with mild symptoms. Cerebrovasc Dis 2009; 27:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/28\">",
"      Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/29\">",
"      Cronin CA, Shah N, Morovati T, et al. No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria. Stroke 2012; 43:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/30\">",
"      Caplan LR. Treatment of acute stroke: still struggling. JAMA 2004; 292:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/31\">",
"      Wein TH, Hickenbottom SL, Morgenstern LB, et al. Safety of tissue plasminogen activator for acute stroke in menstruating women. Stroke 2002; 33:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/32\">",
"      Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997; 28:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/33\">",
"      Kasner SE, Grotta JC. Emergency identification and treatment of acute ischemic stroke. Ann Emerg Med 1997; 30:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/34\">",
"      Demaerschalk BM. Thrombolytic therapy for acute ischemic stroke: the likelihood of being helped versus harmed. Stroke 2007; 38:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/35\">",
"      Michaels AD, Spinler SA, Leeper B, et al. Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. Circulation 2010; 121:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/36\">",
"      Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/37\">",
"      LaMonte MP, Bahouth MN, Magder LS, et al. A regional system of stroke care provides thrombolytic outcomes comparable with the NINDS stroke trial. Ann Emerg Med 2009; 54:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/38\">",
"      Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/39\">",
"      Wahlgren N, Ahmed N, D&aacute;valos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/40\">",
"      Albers GW, Olivot JM. Intravenous alteplase for ischaemic stroke. Lancet 2007; 369:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/41\">",
"      Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/42\">",
"      Katzan IL, Hammer MD, Furlan AJ, et al. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 2003; 34:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/43\">",
"      Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007; 38:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/44\">",
"      Goldstein JN, Marrero M, Masrur S, et al. Management of thrombolysis-associated symptomatic intracerebral hemorrhage. Arch Neurol 2010; 67:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/45\">",
"      Mahaffey KW, Granger CB, Sloan MA, et al. Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries. Am Heart J 1999; 138:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/46\">",
"      Kasner SE, Villar-Cordova CE, Tong D, Grotta JC. Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke. Neurology 1998; 50:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/47\">",
"      Hill MD, Lye T, Moss H, et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 2003; 60:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/48\">",
"      Chodirker WB. Reactions to alteplase in patients with acute thrombotic stroke. CMAJ 2000; 163:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/49\">",
"      Engelter ST, Fluri F, Buitrago-T&eacute;llez C, et al. Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J Neurol 2005; 252:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/50\">",
"      Moser DK, Kimble LP, Alberts MJ, et al. Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council. Circulation 2006; 114:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/51\">",
"      Strbian D, Soinne L, Sairanen T, et al. Ultraearly thrombolysis in acute ischemic stroke is associated with better outcome and lower mortality. Stroke 2010; 41:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/52\">",
"      Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 2011; 123:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/53\">",
"      Sattin JA, Olson SE, Liu L, et al. An expedited code stroke protocol is feasible and safe. Stroke 2006; 37:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/54\">",
"      Grotta JC, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 2001; 58:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/55\">",
"      Gottesman RF, Alt J, Wityk RJ, Llinas RH. Predicting abnormal coagulation in ischemic stroke: reducing delay in rt-PA use. Neurology 2006; 67:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/56\">",
"      Rost NS, Masrur S, Pervez MA, et al. Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke. Neurology 2009; 73:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/57\">",
"      Audebert HJ, Kukla C, Clarmann von Claranau S, et al. Telemedicine for safe and extended use of thrombolysis in stroke: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria. Stroke 2005; 36:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/58\">",
"      Audebert HJ, Kukla C, Vatankhah B, et al. Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany. Stroke 2006; 37:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/59\">",
"      Schwab S, Vatankhah B, Kukla C, et al. Long-term outcome after thrombolysis in telemedical stroke care. Neurology 2007; 69:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/60\">",
"      Meyer BC, Raman R, Hemmen T, et al. Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study. Lancet Neurol 2008; 7:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/61\">",
"      Zaidi SF, Jumma MA, Urra XN, et al. Telestroke-guided intravenous tissue-type plasminogen activator treatment achieves a similar clinical outcome as thrombolysis at a comprehensive stroke center. Stroke 2011; 42:3291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/62\">",
"      Schwamm LH, Holloway RG, Amarenco P, et al. A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke 2009; 40:2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/63\">",
"      Schwamm LH, Audebert HJ, Amarenco P, et al. Recommendations for the implementation of telemedicine within stroke systems of care: a policy statement from the American Heart Association. Stroke 2009; 40:2635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/64\">",
"      Ehlers L, M&uuml;skens WM, Jensen LG, et al. National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: a model of budgetary impact and cost effectiveness. CNS Drugs 2008; 22:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/65\">",
"      Nelson RE, Saltzman GM, Skalabrin EJ, et al. The cost-effectiveness of telestroke in the treatment of acute ischemic stroke. Neurology 2011; 77:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/26/6570/abstract/66\">",
"      Rudolph SH, Levine SR. Telestroke, QALYs, and current health care policy: the Heisenberg uncertainty principle. Neurology 2011; 77:1584.",
"     </a>",
"    </li>",
"    <li>",
"     TRUST-tPA: Therapeutic trial evaluating efficacy of telemedicine (TELESTROKE) of patients with acute stroke. file://clinicaltrials.gov/ct2/show/NCT00279149 (Accessed on March 14, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16134 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-48A44A7773-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6570=[""].join("\n");
var outline_f6_26_6570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H548390\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H548313\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H548320\">",
"      PATIENT SELECTION AND ELIGIBILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H548341\">",
"      Treatment timeline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H209963\">",
"      Role of eligibility criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17846043\">",
"      Use in menstruating women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17846222\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551003\">",
"      MANAGEMENT OF BLOOD PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H548362\">",
"      INTRAVENOUS ALTEPLASE ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H550917\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H550924\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H549875\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33561301\">",
"      Intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549640\">",
"      Management of symptomatic intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549655\">",
"      Systemic bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549662\">",
"      Angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H209311\">",
"      REDUCING DELAYS TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H209318\">",
"      Coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H209325\">",
"      Telemedicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H548390\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/16134\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/16134|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/40/32397\" title=\"table 1\">",
"      Criteria for treating acute stroke with tPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/29/34268\" title=\"table 2\">",
"      Treating hypertension in acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/60/22475\" title=\"table 3\">",
"      Management of ICH after thrombolysis for ischemic stroke",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=related_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_26_6571="Glomerular v extraglom in child";
var content_f6_26_6571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distinguishing extraglomerular from glomerular hematuria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Extraglomerular",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glomerular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Color (if macroscopic)",
"       </td>",
"       <td>",
"        Red or pink",
"       </td>",
"       <td>",
"        Red, smoky brown, or \"Coca-Cola\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clots",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proteinuria",
"       </td>",
"       <td>",
"        Usually absent",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RBC morphology",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Dysmorphic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RBC casts",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6571=[""].join("\n");
var outline_f6_26_6571=null;
var title_f6_26_6572="Predictors of complications at the time of coronary angiography";
var content_f6_26_6572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Multivariate predictors of major complications of coronary angiography (based on 58,332 procedures)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Odds ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moribund",
"       </td>",
"       <td>",
"        10.22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shock",
"       </td>",
"       <td>",
"        6.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute MI &lt;24 h",
"       </td>",
"       <td>",
"        4.03",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal insufficiency",
"       </td>",
"       <td>",
"        3.30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiomyopathy",
"       </td>",
"       <td>",
"        3.29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic valve disease",
"       </td>",
"       <td>",
"        2.72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitral valve disease",
"       </td>",
"       <td>",
"        2.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure",
"       </td>",
"       <td>",
"        2.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        New York Heart Association Functional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Class I",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.00",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Class II",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Class III",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Class IV",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td>",
"        1.45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unstable angina",
"       </td>",
"       <td>",
"        1.42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Outpatient/inpatient",
"       </td>",
"       <td>",
"        0.63",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Moribund indicates a patient who responds poorly due to a life threatening condition.",
"    <div class=\"footnotes\">",
"     MI: myocardial infarction.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Scanlon, PJ, Faxon, DP, Audet, AM, et al, J Am Coll Cardiol 1999; 33:1756.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6572=[""].join("\n");
var outline_f6_26_6572=null;
var title_f6_26_6573="Comparison of cephalosporin and penicillin structures";
var content_f6_26_6573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Comparison of cephalosporin and penicillin structures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 144px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cephalosporins and penicillins share a four-membered beta-lactam ring. Cephalosporins have a six-membered dihydrothiazine ring, while penicillins have a five-membered thiazolidine ring. The R1, and to a lesser extent, the R2 side groups on cephalosporins are important in generating allergenic epitopes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Antonino Romano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6573=[""].join("\n");
var outline_f6_26_6573=null;
var title_f6_26_6574="PET rapid vs slow transporters";
var content_f6_26_6574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peritoneal equilibration test in rapid versus slow transporters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 332px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Differences between rapid and slow transporters during PD. Rapid transporters reach creatinine equilibration more quickly (dialysate- to-plasma creatinine equals one, top panel), have a gradual reduction in dialysate volume after two hours due to glucose absorption (middle panel), and have a reduction in creatinine clearance (Ccr) after four hours due to absorption of creatinine with the glucose and fluid (lower panel). Thus, short dwell times are most efficient in these patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Twardowsky ZJ, ASAIO Trans 1990; 36:8.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6574=[""].join("\n");
var outline_f6_26_6574=null;
var title_f6_26_6575="Urea cycle disorders";
var content_f6_26_6575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Urea cycle disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 400px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Asterisks represent the source of nitrogen for urea formation. Precursor amino acids contributing to the nitrogen pool include glutamine, glycine, and alanine.",
"    <div class=\"footnotes\">",
"     CPS: carbamyl phosphate synthetase; OTC: ornithine transcarbamylase; ASS: argininosuccinate synthetase; ASL: argininosuccinic acid lyase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_26_6575=[""].join("\n");
var outline_f6_26_6575=null;
